Breast Cancer Risk after Metformin Initiation in Older Women: the Role of Study Design, Potential Confounding by Body Mass Index, and Differential Detection by Hong, Jin-Liern
BREAST CANCER RISK AFTER METFORMIN INITIATION IN OLDER WOMEN: 
 THE ROLE OF STUDY DESIGN, POTENTIAL CONFOUNDING BY BODY MASS INDEX, 
 AND DIFFERENTIAL DETECTION 
Jin-Liern Hong 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department 
of Epidemiology in the Gillings School of Global Public Health. 
Chapel Hill 
2015 
Approved by: 
Til Stürmer 
Michele Jonsson Funk 
John Buse 
Louise M. Henderson 
Jennifer L. Lund 
  
 ii 
©  2015 
Jin-Liern Hong 
ALL RIGHTS RESERVED
 iii 
ABSTRACT 
Jin-Liern Hong: Breast Cancer Risk after Metformin Initiation in Older Women: the Role of 
Study Design, Potential Confounding by Body Mass Index, and Differential Detection 
(Under the direction of Til Stürmer) 
Several observational studies reported that metformin may reduce breast cancer risk; 
however, many of these studies were affected by time-related biases. Additionally, confounding 
by unmeasured body mass index (BMI) and differential detection for breast cancer have not been 
examined in metformin-breast cancer studies. The dissertation aimed to examine the relative risk 
of breast cancer for older women initiating metformin versus sulfonylureas, avoiding time-
related bias and accounting for potential bias due to unmeasured confounding and differential 
screening mammography. 
Using 2007-2011 US Medicare claims data, we identified cohorts of cancer-free women 
aged 65+ who initiated monotherapy with metformin or sulfonylureas. Hazard ratios of breast 
cancer were estimated comparing metformin to sulfonylureas initiators, using weighted Cox 
models. Unmeasured confounding by BMI and smoking was adjusted by propensity score 
calibration using external information from Medicare Current Beneficiary Survey 2006-2009 
panels. Among new users of Medicare claims, we compared the risks of screening mammograms 
and screen-detected breast cancer in 12 months pre- and post-initiation between metformin and 
sulfonylureas initiators.   
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Metformin initiators did not have reduced risks of breast cancer compared with 
sulfonylureas initiators (Hazard Ratio: 1.08; 95% Confidence Interval: 0.81 to 1.44). Externally 
controlling for BMI and smoking did not affect the estimate, indicating a little independent effect 
of BMI and smoking on metformin relative to sulfonylureas prescribing. Metformin initiators 
were not only more frequently screened for breast cancer than sulfonylureas initiators, but they 
also had higher probabilities of screen-detected breast cancer both in 12 months before and after 
initiation. The results indicate possible detection bias due to differential screening 
mammography, but the absolute difference in screen-detected breast cancer is too small to 
explain observing no metformin-breast cancer association assuming a real protective effect of 
metformin.  
This study provides no support for reduced risks of breast cancer after initiation of 
metformin compared with a clinical alternative, sulfonylureas, in older women. Our findings 
support the notion that reduced breast cancer risks in metformin users observed in previous 
studies is likely due to time-related biases, and emphasize the importance of conducting 
observational studies with rigorous, state-of-the art design to avoid observing spurious effects or 
missing real ones.  
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CHAPTER 1. STATEMENT OF SPECIFIC AIMS 
Several observational studies have shown the beneficial effect of metformin on the risk of 
breast cancer [1-5]. A meta-analysis of seven observational studies found a decreased risk of 
breast cancer with metformin [Odds Ratio (OR): 0.83; 95% Confidence Interval (CI): 0.71-0.97)] 
and a slightly stronger association with longer metformin use (>3 years) (OR: 0.75; 95% CI: 
0.62-0.91) [6]. However, methodological flaws exist in most studies, including the lack of well-
defined active comparator group, bias from immortal-time in cohort studies, and from time-
window bias in case-control studies [7]. Furthermore, little is known about unmeasured 
confounding by body mass index (BMI) and smoking status and whether there is differential 
detection for breast cancer between metformin and sulfonylureas initiators in metformin-breast 
cancer studies.   
The goals of this study were to compare the risk for breast cancer in older adults initiating 
metformin with those initiating sulfonylureas, using a state of the art study design, and to explore 
concerns about unmeasured confounding and differential screening mammography, using data 
from Medicare Beneficiaries and Medicare Current Beneficiary Survey. This study does not only 
add to the understanding of the breast cancer risk in diabetic patients who initiate metformin or 
sulfonylureas, but also provides new information on some important factors at the time of 
treatment initiation which are usually unavailable in claims data and on differences in screening 
mammography. 
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The following specific aims were addressed in this research: 
Aim 1a: To estimate the relative risk for breast cancer in metformin initiators, compared with 
sulfonylureas initiators, using data from Medicare Beneficiaries.  
Hypothesis: We hypothesize that metformin does not affect the risk of breast cancer 
among older women.  
Rationale: Among several observational studies indicating benefits of metformin on 
breast cancer, most were affected by time-related bias (i.e., immortal time bias, time 
window bias, and lag-time bias). These biases would lead to an apparent protective effect 
in the absence of a real effect or magnify any potential beneficial effect of metformin on 
cancer incidence [7]. Thus, the observed reduction in the risk of breast cancer associated 
with metformin is likely attributed to time-related bias. 
Aim 1b: To examine the impact of BMI and smoking status on physicians’ choice of metformin 
versus sulfonylureas, using data from the Medicare Current Beneficiary Survey, and to quantify 
unmeasured confounding by BMI and smoking status on metformin-breast cancer association.  
Hypothesis: We hypothesize that BMI and smoking status affect physician decision to 
prescribe metformin versus sulfonylureas to diabetic patients.  
Rationale: Previous studies suggest potential effects of metformin on cancer prevention; 
therefore, it is possible that physician may tend to prescribe metformin to those diabetic 
patients who are at high risk for cancer, such as current smoker and overweight/obese 
persons. In addition, Metformin has been shown to be moderately associated with weight 
loss in randomized clinical trials [8, 9], thus obese, diabetic patients are more likely to 
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receive metformin than a clinical alternative, sulfonylureas. Therefore, given that both 
factors are associated with increased risks of breast cancer in postmenopausal women [23, 
25, 45], unmeasured BMI and smoking status may confound the association between 
metformin and breast cancer risk. 
Aim 2: To compare the probability of receiving screening mammography and the incidence of 
screen-detected breast cancer between metformin and sulfonylureas initiators in the 12 months 
before and after initiation, using data from Medicare Beneficiaries  
Hypothesis: We hypothesize that metformin initiators are more likely to receive screening 
mammography than sulfonylureas initiators in the 12 months pre- and post-initiation.  
Rationale: Metformin is recommended as the first line treatment for type 2 diabetes [8], 
thus metformin prescribers who comply with guideline recommendations may be more 
likely to perform regular examinations or to recommend cancer screening tests for older 
patients. Previous studies also have shown that physician recommendation is one strong 
motivation for undergoing screening mammography [69, 70]. Therefore, women 
initiating metformin may be more likely to receive screening mammography and, 
consequently, to be diagnosed with breast cancer around the time of initiation. 
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CHAPTER 2. REVIEW OF LITERATURE 
I. Metformin 
Metformin is an oral anti-hyperglycemic agent of the biguanides class and is the first line 
treatment for type 2 diabetes mellitus [10].  Metformin can lower hyperglycemia by inhibiting 
glucose production in the liver (hepatic gluconeogenesis), decreasing the absorption of glucose 
in the intestine, and increasing insulin sensitivity [11]. Compared with other anti-hyperglycemic 
drugs, metformin has low risks of hypoglycemia and minor side effects. The common side 
effects of metformin include stomach or abdominal discomfort, diarrhea, muscle pain or 
weakness, and decreased appetite. Additionally, metformin may induce lactic acidosis, which is a 
rare but severe adverse effect and usually occurs in diabetic patients with impaired renal function 
[12]. 
Metformin has been shown to help facilitate weight loss [8, 9] and to effectively delay or 
prevent developing diabetes in patients with pre-diabetes [8, 9, 13, 14], identified by impaired 
fasting glucose, impaired glucose tolerance, or elevated HbA1c according to American Diabetes 
Association [10]. In addition to treatment of hyperglycemia, metformin is also used to treat 
polycystic ovary syndrome [15, 16]. Some studies also suggest that metformin may have 
beneficial effect on prevent the cardiovascular disease [17-19].  
Recently, metformin has received much attention due to its potential beneficial effect on 
cancer prevention and treatment, in particular, on breast cancer [20-22]. Evidence from 
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preclinical and clinical studies has suggested that metformin has anti-tumor ability and may 
reduce incidence and mortality of breast cancer [23, 24]. 
II. Plausible mechanism for antitumor action of metformin 
The mechanism of metformin action on breast cancer is unclear but it is generally 
believed to involve both direct and indirect action through mediating adenosine monophosphate-
activated protein kinase-activated protein kinase (AMPK). AMPK is an enzyme which plays an 
important role in cellular energy homeostasis. Metformin can activate AMPK to directly inhibit 
cellular protein synthesis and cell proliferations in both normal and cancer cells, through 
suppression of the mammalian target of rapamycin (mTOR) pathway.  mTOR is a type of protein 
which regulates protein synthesis and cell growth/proliferation. On the other hand, activation of 
AMPK also can inhibit transcription of key gluconeogenesis genes in the liver and stimulate 
glucose uptake in muscle; as a result, metformin can reduce the levels of circulating glucose and 
insulin and can increase the insulin sensitivity, thus indirectly inhibiting carcinogenesis and 
cancer prognosis [25, 26]. 
III. Clinical Studies of the effect of metformin on the risk of breast cancer 
The risk of breast cancer associated with metformin has been examined in ten 
observational studies and two clinical trials [1-5, 27-32]. Four studies compared the breast cancer 
risk of metformin with no use of metformin, three of which reported that metformin reduced the 
risk of breast cancer [1, 2, 4, 28]. The strongest effect was observed in a case-control study 
within UK Clinical Practice Research Datalink (CPRD, formally known as General Practice 
Research Database, GPRD) [1]. Among women aged 30-79 and diagnosed with type 2 diabetes, 
long-term use of metformin (≥ 40 prescriptions) showed a strong effect on preventing breast 
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cancer, compared with no use of metformin [Odds Ratio (OR): 0.42; 95% Confidence Interval 
(CI): 0.21-0.87]. A similar but weaker beneficial effect was observed in one Danish case-control 
study and one UK cohort study [2, 4].  The case-control study nested in women with type 2 
diabetes in Danish Medical Registries found that metformin use was associated with a reduced 
risk of breast cancer (OR: 0.81; 95% CI: 0.63-0.96) [2]. In a cohort study of the Diabetes Audit 
and Research in Tayside Study, Scotland, metformin user had a decreased risk of breast cancer 
compared with nonusers of metformin matched on the year of diabetes diagnosis [Hazard Ratio 
(HR): 0.60; 95% CI: 0.32-1.10] [4].  However, among older women with diabetes and receiving 
treatment of glargine or nonglargine insulin enrolled in Medicare, metformin was shown to 
increase the risk of breast cancer compared with no use of metformin (HR: 1.28; 95% CI: 1.05-
1.57) [28]. 
The breast cancer risks of metformin and other oral anti-diabetic drugs have been 
compared with one another in six studies [5, 27, 29-31]. The significantly inverse association 
between metformin and breast cancer was only found in a cohort study of PHARMO Record 
Linkage System in the Netherlands [5]. The risk of breast cancer slightly decreased in new users 
of metformin, compared with new users of sulfonylureas (HR: 0.95; 95% CI: 0.91-0.98). The 
other study comparing metformin use versus sulfonylureas use in the CPRD showed no evidence 
of a reduced risk of breast cancer (HR: 1.04; 95% CI: 0.79-1.37) [30]. Two UK cohort studies 
comparing sulfonylureas with metformin also showed no altered risk of breast cancer, using data 
from THIN (HR: 1.04; 95% CI: 0.79-1.37) and CPRD (HR: 0.98; 95% CI: 0.61-1.41) [27, 29]. 
No beneficial effect of metformin on breast cancer was also found in re-analyses of two clinical 
trials: A Diabetes Outcome Progression Trial (ADOPT) and Rosiglitazone Evaluated for 
Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes (RECORD) [31]. In ADOPT 
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with a median treatment and follow-up time of 4.0 years, six (1.0%) and six (0.9%) patients 
developed breast cancers among 590 patients randomized to metformin compared with 645 
patients randomized to rosiglitazone, with a HR of 1.09 (95% CI: 0.35-3.41). In the RECORD 
study patients on sulfonylureas were randomized to metformin or Rosiglitazone and treated and 
followed over 5.5-years. Of the 554 patients randomized to metformin, 8 (1.4%) developed 
breast cancer compared with 4 (0.7%) among 562 patients randomized to rosiglitazone, resulting 
in a HR of 2.04 (95% CI: 0.61-6.83).  
Additionally, one study examined the risk of breast cancer associated with metformin use 
among postmenopausal women from Women Health Initiative (WHI) clinical trials with an 
average of 11.8 years follow-up [3].  Diabetic women initiating metformin had a decreased risk 
of breast cancer compared with non-diabetic women (HR: 0.75; 95% CI: 0.57-0.99). The breast 
cancer risk in metformin users has been also examined over time [32]. Metformin users showed a 
pattern of decreasing breast cancer over time. The incidence rate ratio was 0.73 (95% CI: 0.56-
0.96) during months 6-24, 0.91 (95% CI: 0.70-1.17) during months 25-60, and 0.82 (95% CI: 
0.61-1.10) during months 60+, compared with the initial 6 months after starting treatment. 
Although the results are not consistent, a recent meta-analysis found a decreased risk of 
breast cancer associated with metformin (OR: 0.83; 95% CI: 0.71-0.97) and a stronger 
association with longer metformin use (>3 years) (OR: 0.75; 95% CI: 0.62-0.91) [6]. This 
beneficial effect was subsequently supported by another meta-analysis (OR: 0.94; 95% CI: 0.91-
0.99) [33]. However, results and study designs of these published studies are very heterogeneous 
and thus the usefulness to combine these into a single summary estimate is questionable.  Choice 
of comparison group, for example, varied widely across studies. Estimates comparing metformin 
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with no use of metformin suggest more beneficial effect than those comparing metformin with 
other anti-diabetics drugs.  
IV. Methodological concerns on available literature 
Despite the vast body of observational studies on the breast cancer risk of metformin, 
majority of these studies had flaws in study design (Table 2.1). The most important problem are 
time-related biases, as pointed out by Suissa and Azoulay [7].  Time-related biases, including 
immortal time bias, time-window bias, and bias from time lag and latency, likely exaggerate the 
potential beneficial effect of metformin on cancer incidence. Thus, the reduced risk of breast 
cancer observed in current literature could be attributed, at least in part, to time-related biases. 
Among the 12 metformin-breast cancer studies, five are subject to time-related biases: two suffer 
from immortal time bias [27, 30]; two from time-window bias [1, 2]; and two from time-lag bias 
[4, 27]. In addition to time-related biases, numerous methodological issues and limitations 
should be also noted. Firstly, some studies used Cox models with time-varying exposure but 
failed to consider time-varying confounders [3, 30]. Any prescription change of oral anti-diabetic 
medications highly correlates with control of blood glucose. Patients with poorly controlled 
glucose level are more likely to switch to or to receive additional anti-diabetic drugs. Secondly, 
the WHI study may be subject to recall bias and exposure misclassification because information 
on diabetes diagnosis and medication was retrieved from questionnaires in year 0, 1, 3, and 6 [3]. 
Third, in re-analyses of ADOPT and RECORD clinical trials, the number of breast cancer cases 
was less than ten, which may not be large enough to generate a valid estimate with a precise 
confidence interval [31]. Also, clinical trial tends to recruit young and healthy patients, and thus, 
the results may not be generalizable to the overall population of metformin users. For the only 
study which examined the breast cancer risk of metformin over time, it is misleading to imply 
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beneficial effects of long-term metformin use by comparing metformin user who had longer 
follow-up time with metformin users who had follow-up time less than 6 months [32]. 
Characteristics between patients with long follow-up time and those with short follow-up time 
might be different. For example, healthier patients are likely to have longer follow-up times and 
maybe less likely develop cancer. Lastly, confounding is not well controlled for in some studies, 
even in the studies with active comparison groups [5, 29]. Although both metformin and 
sulfonylureas are used for diabetes treatment, patient characteristics for these two drugs may 
differ, such as comorbidity and concurrent medication use. 
Apart from the methodological flaws and limitation described above, unmeasured 
confounding by body mass index (BMI) and smoking status and detection bias are another 
problem which has not been addressed in metformin-cancer studies. BMI and smoking are 
positively associated with the risk of several types of cancers. For breast cancer, obese women 
after menopause have about 20% higher risk of developing breast cancer than women with 
normal weight [34], but it remains controversial whether smoking affects breast cancer incidence 
[35-37]. Given the beneficial effect of metformin on weight loss and a heated discussion about 
benefits of metformin on cancer, physicians may preferably prescribe metformin to overweight 
or obese patients, as well as smokers [10]. Thus, the association between metformin and breast 
cancer could be confounded by BMI and smoking status. Some studies controlled for BMI and 
smoking status. The potential magnitude of confounding by BMI and smoking has not been 
evaluated in any study, however.  
Detection bias has been studied in diabetes-cancer studies, but little is known in 
metformin-cancer studies [38]. It is reasonable to suspect the existence of detection bias in 
metformin-cancer studies of older population. According to the guidelines, metformin is 
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recommended as the first line treatment for diabetes, except for patients with chronic kidney 
disease [10]. Therefore, physicians who prescribe metformin as initial treatment rather than any 
other anti-diabetic drug follow the guidelines and might also be more likely to perform regular 
examinations or recommended cancer screening tests for older patients who are at high risk for 
several types of cancers compared with their peers who do not. Differential detection before 
initiation could reduce cancer incidence by early diagnosis and removal of (asymptomatic or pre-
clinical) cancer.  On the other hand, differential detection after initiation may lead to an 
increased risk immediately following treatment initiation. This speculation could be supported in 
breast cancer by the UK study [32]. Among metformin users aged 40 or over in the CPRD, the 
breast cancer risk is higher in the first 6 months than later. Unfortunately, no study has attempted 
to address this issue.  
Due to concerns about the important time-related bias and potential confounding in 
metformin-breast cancer studies, the effect of metformin on the risk of breast cancer remains 
unresolved [7]. Thus, we conducted a cohort study to investigate the effect of metformin on the 
risk of breast cancer in postmenopausal women using a state of the art nonexperimental study 
design, and to assess the impact from unmeasured confounding by BMI and smoking status as 
well as detection bias, using data from a US wide sample of Medicare beneficiaries. 
V. Significance 
Breast cancer is the most common cancer for women worldwide and in the United States. 
The Surveillance, Epidemiology, and End Results (SEER) program estimated approximately 
232,340 new cases of breast cancer in the year of 2013, accounting for 14.1% of all new cancer 
cases in the US [47].  The cost of breast cancer care in 2010 was estimated at 16.5 billion dollars 
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in US, the highest among all cancer sites [48]. Diabetes is positively associated with the risk of 
breast cancer, increasing risk around 20 to 40% in women [49].  As a preferred treatment for 
diabetes, metformin’s potential benefits on breast cancer risk may have clinical interest and 
implications. In addition, the National Cancer Institute highlighted the potential effects of 
metformin on cancer prevention as well as some important ongoing clinical trials in their April 
2013 Cancer Research Update [50]. Therefore, it is needed to elucidate whether metformin 
reduces the risk of breast cancer in high risk populations, by conducting an observational study 
with state of the art methodology and rigorous design, which avoids immortal time bias and 
addresses potential confounding by BMI and differential detection for breast cancer. 
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VI. Tables 
TABLE 2.1. Methodological concerns in previous metformin-cancer studies 
Study 
Study 
Design 
Exposure vs 
Comparison 
Methodological Concerns or Limitations 
Currie 2009 [27] Cohort MET vs SUL Immortal Time Bias; Time-Lag Bias 
Libby 2009 [4] Cohort MET vs No MET Time-Lag Bias 
Home 2010 [31] RCT MET vs ROSI 
MET vs Glyburide 
Re-analysis of clinical randomized trial (ADOPT); 
very small number of breast cancer cases (<10 each 
group) 
Home 2010 [31] RCT MET+SUL vs 
MET+ROSI 
Re-analysis of clinical randomized trial (RECORD); 
very small number of breast cancer cases (<10 each 
group) 
Bosco 2011 [2] Case-
Control 
MET vs No MET Time-Window Bias 
Morden 2011 [28] Cohort MET vs No MET Prevalent users; Examining metformin effect on a 
background of glargine or non-glargine insulin 
Bodmer 2012 [1] Case-
Control 
MET vs No MET Time-Window Bias 
Chlebowski 2012 [3] Cohort DM DX+MET vs 
NO DM 
Recall Bias from Survey; Exposure misclassification; 
Failure to consider time-varying confounders 
Redaniel 2012 [30] Cohort SUL vs MET Immortal Time Bias; Failure to consider time-varying 
confounders 
Ruiter 2012 [5] Cohort MET vs SUL Not considering other potential confounders, such as 
comorbidity and current medication use. 
Van Staa 2012 [32] Cohort Duration of MET 
use 
It is misleading to imply beneficial effect of long-
term metformin use by comparing metformin user 
who had longer follow-up time with metformin users 
who had follow-up time less than 6 months. 
Qui 2013 [29] Cohort SUL vs MET Not considering other potential confounders, such as 
comorbidity and current medication use. 
Abbreviations: DM: Diabetes; MET: metformin; SUL: sulfonylureas; No MET: no use of metformin; ROSI: 
rosiglitazone; RCT: Randomized Trial 
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CHAPTER 3. METHODS 
I. Overall Strategy 
This study conducted a cohort study with new user design to examine the risk of breast 
cancer after metformin compared with sulfonylureas initiation, using 2007-2011Medicare claims 
data. Cross-sectional studies was also conducted to quantify the effects of BMI and smoking 
status, which are unmeasured in Medicare claims data, on initiation of metformin versus 
sulfonylureas as external control, using data from the Medicare Current Beneficiary Survey 
(MCBS) 2006-2009 panels. We further assessed the impacts of unmeasured confounding by 
BMI and smoking status on the association between breast cancer risk and metformin in 
Medicare data. In addition, to investigate the potential detection bias in a study of the effects of 
anti-hyperglycemic drugs on breast cancer risk, we described patterns of breast cancer screening 
examinations over 12-months period pre- and post-initiation of metformin and sulfonylureas by 
summarizing frequency of screening mammography within 3-month intervals in the new user 
cohorts based on Medicare claims data, and estimated the risk difference of receiving screening 
mammography comparing metformin initiators with sulfonylureas initiators over a total of two-
year period. 
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II. Data Source 
1. Medicare Beneficiaries  
Medicare is funded by United States (US) federal government and is administered by the 
Center of Medicare and Medicaid Services.  Medicare provides medical coverage for citizens 
aged 65 years and older, with certain disabilities, or with End-Stage Renal Disease (ESRD). In 
2010, 47 million persons were enrolled in Medicare, of whom 8 million were disabled persons or 
persons with ESRD under age 65 [40].  The Medicare database is composed of three types of 
data files: Part A (hospital claims), Part B (outpatient physician services), and Part D (dispensed 
prescription claims), capturing patient information including demographics, diagnosis and 
procedure codes, along with claims for dispensed prescriptions. All clinical data are recorded by 
the Classification of Disease 9
th
 Revision (ICD-9), Current Procedural Terminology-4 (CPT-4) 
codes, and the Healthcare Common Procedure Coding System (HCPCS). Dispensed 
prescriptions are coded using National Drug Codes (NDCs). In this study, we identified our 
study cohort from twenty percent of the entire fee-for-service Medicare population.  
2. Medicare Current Beneficiary Survey (MCBS) 
The Medicare Current Beneficiary Survey (MCBS) is a continuous, multipurpose survey 
of a nationally representative sample of the Medicare beneficiaries, conducted by the Office of 
Information Products and Data Analysis (OIPDA) of the Centers for Medicare & Medicaid 
Services. The MCBS contains data on socioeconomic, demographic characteristics, health status 
and functioning, health care use, health insurance coverage, and Medicare claims for survey 
participants.  This survey has a high response rate (between 85% and 95%) and very high degree 
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of data completeness [41-43]. The MCBS includes two modules: Access to Care, and Cost and 
Use Files, and we used the module of Cost &Use Files in this study.  
III. Study Population 
1. Study Cohort from Medicare Beneficiaries 
Study cohort for Aim 1a (Breast Cancer Risk) 
Eligibility requirements for women to be included in this study were: (1) continuous 
enrollment in Medicare Part A, B, and D for at least 6 months prior to treatment initiation 
during the period from 2007 to 2011, (2) age of 65 years or more at treatment initiation, (3) 
new users of metformin or sulfonylureas with at least 1 refill within 90 days after end supply 
of the index prescription, and (3) free of kidney disease and any type of cancers except for 
non-melanoma skin cancer within 6 months prior to treatment initiation. New use was 
defined as not receiving any anti-diabetic treatment within 6 months prior to initiation of 
metformin or sulfonylureas, including oral and injection anti-diabetic drugs and insulin or its 
analogues. Patients were categorized into the cohorts of metformin or sulfonylureas 
according to the first prescription (index prescription). To increase the likelihood that 
patients are actually exposed to the drug, eligible new users were required to have at least 
one refill of index prescription within 90 days after end of drug supply of index prescription. 
The date of the first refill was defined as the index date.   
In this study, we did not restrict the study cohort by requiring diagnosis of diabetes 
prior to treatment initiation because both metformin and sulfonylureas are used almost 
exclusively for treatment of type 2 diabetes. Although women with polycystic ovary 
syndrome (PCOS) may receive metformin for treatment, PCOS occurs in older women very 
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rarely. Thus, given our study cohort consisting of women aged 65 and over, all initiators of 
metformin or sulfonylureas can be considered as truly having type 2 diabetes mellitus.   
Study cohort for Aim 2 (Screening Mammography) 
To address different effects due to differential detection pre- and post-initiation, we 
included two study cohorts in the study of Aim 2. One was the new user cohort which was 
used to examine use of screening mammography over a two-year window of 12 months pre- 
and post-initiation, primarily focusing on the period of 12 months prior to initiation. The 
other study cohort was the cancer-free cohort mimicking a cohort study on breast cancer 
incidence, which only examined use of screening mammography in 12 months after initiation.  
Similar inclusion criteria of Aim 1a (Breast Cancer Risk) were used to select study 
cohorts for Aim 2. For the new user cohort, we identified women aged 65 or older who 
initiated monotherapy of metformin or sulfonylureas between 2008 and 2010, in order to give 
potential two-year enrollment period before and after initiation for examining receipt of 
screening mammography. Initiation was defined as having at least one refill within 90 days 
after end of drug supply of the initial prescription and having at least 12 months of 
continuous Part D enrollment prior to initiation without use of any anti-diabetic drugs. 
Patients were classified as new users of metformin or sulfonylureas according to the initial 
prescription and the date of the first prescription was defined as the index date (i.e., 
initiation). Eligible patients were also required to have enrolled in Part A and B continuously 
for ≥ 24 months pre-initiation and ≥ 12 months post-initiation, thus patients who died or 
disenrolled Medicare Part A and B within 12 months after initiation were excluded from the 
study.  
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A study examining cancer incidence commonly requires a cancer-free study 
population. Thus, we had the cancer-free cohort to correctly assess receipt of screening 
mammography within 12 months following treatment initiation. This cancer-free cohort was 
a subgroup of the new user cohort, which included eligible initiators without a diagnosis of 
any cancer except for non-melanoma skin cancer within 12 months prior to initiation.  
2. Study Cohort from Medicare Current Beneficiary Survey (MCBS) 
To address the specific aim 1b (Unmeasured Variables), we conducted an external 
validation study using data from MCBS 2006-2009 panels. We identified new users of 
metformin or sulfonylureas of both genders from all MCBS participants, using data from the file 
of Prescribed Medicine Events in MCBS Cost & Use files (equivalent to Medicare Part D 
prescription files). The number of eligible patients in MCBS was expected small, thus initiation 
was defined by requiring only one prescription and new use was defined as no prescription for 
metformin or sulfonylureas in 6 month prior to initiation of monotherapy of metformin or 
sulfonylureas. 
IV. Variables of Interests 
1. Variables of Interests for Specific Aim 1a (Breast Cancer Risk) 
Exposure and Follow-up 
Exposure was defined as metformin or sulfonylureas according to dispensed 
prescription and its refill claims in Medicare Part D.  
Two approaches were undertaken to define follow-up time: the as-treated (AT) and 
the intention-to-treat (ITT) analyses. In addition, because the primary outcome was breast 
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cancer which has a long preclinical phase, we incorporated the assumptions of induction and 
latency periods of 180 days each in the analysis.  In AT approach, follow-up started on 180 
days after the index date, and ended with the earliest of the following events: 180 days after 
augmentation or discontinuation of treatment, any cancer diagnosis except for non-melanoma 
skin cancer, death, end of enrollment in Medicare part D for greater than 1 month, or end of 
study (December 31st, 2011). Augmentation was defined as a subsequent addition of other 
anti-diabetic drugs to index prescription. Treatment discontinuation was defined as no further 
refill within the days of supply plus a 90-day grace period. Secondly, ITT analysis would 
follow-up patients from 180 days after the index date and until the date of any cancer 
diagnosis except for non-melanoma skin cancer, death, or end of study, irrespective of any 
treatment discontinuation or treatment change.  
Outcome 
The outcome was diagnosis of incident breast cancer during follow-up, including both 
in situ and invasive breast cancer. The definition for cancer event was at least two diagnoses 
of breast cancer on different dates within 60 days.  The date of the first diagnosis was defined 
as outcome date. This algorithm has been validated in the Medicare data [44].  
2. Variables of Interests for Specific Aim 1b (Unmeasured Variables) 
Exposure  
The main exposures of interest were BMI and self-reported smoking status. Data on 
height, weight, and smoking status were extracted from MCBS Cost & Use Survey data. 
BMI was calculated by weight (kilogram) divided by height (meter) squared, and was treated 
as a continuous variable and a categorical variable as follows: (1) <25 as normal; (2) ≥25 and 
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<30 as overweight; (3) ≥30 as obese, according to WHO criteria [45].  Smoking status was 
considered as a binary variable (never and ever smoker). Missing data on weight, height, and 
smoking status are possible in MCBS data, but was uncommon (< 5%). 
Outcome 
In the validation study of MCBS, the outcome was initiation of metformin, compared 
with initiation of sulfonylureas. Definition has been described above. 
3. Variables of Interests for Specific Aim 2 (Screening Mammography) 
Screening Mammography 
We used the following the Healthcare Common Procedure Coding System (HCPCS) 
codes to select all mammograms for the study cohort: G0202-G0205, 76091-76092, 77051-
77052, and 77056-77057. Mammograms were further classified as screening versus 
diagnostic test based on a claims-based algorithm [67]. Briefly, mammograms were 
considered as screening test if they were coded as screening mammography without a 
previous mammogram within prior 9 months and without any breast cancer diagnosis in the 
prior year. This algorithm has been validated in Medicare claims with a high positive 
predictive value (PPV) of 94.9% [67].  
Screen-Detected Breast Cancer 
After distinguishing screening from diagnostic mammograms, we also used the 
Fenton algorithm to identify incident screen-detected breast cancers [68]. This algorithm has 
a high PPV of 88.0% among Medicare enrollees [68]. The Fenton algorithm classifies 
screening mammograms as positive to detect breast cancer by requiring a breast cancer 
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diagnosis within 123 days post-mammogram and a breast-directed surgery within a year 
following the diagnosis, or by a diagnosis of carcinoma in-situ within 286 days post-
mammogram with a subsequent mammogram within 82 days following the diagnosis. The 
detail of this algorithm and the results were shown in Supplemental Figures S4-S5.  To 
evaluate the performance of screening mammography in our cohorts, we calculated the 
screening detection rate for breast cancer by dividing the number of screen-detected breast 
cancers by the number of screening mammograms.  
Incident Breast Cancer 
In the cancer-free cohort, any incident breast cancer during 12-month follow-up was 
another outcome of interest, irrespective of whether it was detected by screening or due to 
symptoms. To be similar to the Fenton algorithm, we required a breast-directed surgery 
within a year following a breast cancer diagnosis code, including invasive and carcinoma in 
situ, to ascertain the breast cancer case.  
V. Confounding Control 
Relevant to Specific Aims 1a (Breast Cancer Risk) and 1b (Unmeasured Variables) of the 
proposed study, all covariates were defined based on available information within the 6-month 
period prior to and on the index date. Covariates of interest include: 
(1) Demographics: Age in years (continuous variable), Gender (female or male), Race 
(White, Black, Others). 
(2) Co-morbidity: Benign Breast Disease, Benign Neoplasma of Breast, Chronic 
Obstructive Pulmonary Disease (COPD), Chronic Heart Failure (CHF), Chronic 
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Kidney Disease (CKD), Acute Kidney Injury (AKI), Ischemic Heart Disease, 
Hypertension, Osteoporosis. All co-morbidity variables were categorized into binary 
variables (Yes or No), defined as at least one diagnosis code.  
(3) Medications: Estrogen, Progestin, Statins, Bisphosphonates, ACE inhibitors, ARBs, 
Beta Blockers, Antidepressant, Digoxin, Oral Contraceptives, Calcium Channel 
Blockers, Cholesterol Absorption Inhibitor, Loop Diuretics, non-Loop Diuretics. All 
medication variables were categorized into binary variables (Yes or No), defined as 
at least one prescription or refill records.  
(4) Healthcare System Use: Number of Hospitalization, Days of Hospitalization, 
Number of Physician Visit, Number of Emergency Room Visit, Number of 
Mammography Exams, Number of Lipid Tests. All healthcare system use variable 
were treated as both continuous variables and categorical variables.  
We applied propensity score (PS) methods to control potential confounding [46]. For 
each patient, the probability of receiving metformin versus sulfonylureas was estimated by using 
a logistic regression model which included all covariates as independent variables, as known as 
estimated propensity score (EPS). We implemented the standardized mortality or morbidity ratio 
(SMR) weighting method to balance two cohorts on covariates at baseline. In SMR weighting 
method, we controlled for all these covariates by standardizing to their distribution in the 
metformin initiators using weights of 1 for metformin initiators and the odds of propensity score 
for sulfonylureas initiators [47]. 
To address the specific Aim 2 (Screening Mammography), we assessed the confounding 
effect by age, gender, race/ethnicity, number of physician visits, and calendar year of initiation. 
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VI. Statistical Analysis 
All analyses were performed with the SAS software, 9.3 version.  
1. Analyses to address Specific Aim 1a (Breast Cancer Risk) 
We began with descriptive analyses of study cohorts by variables listed in confounding 
control, and repeated with adjustment of SMR weighting to examine the balance between two 
cohorts after controlling confounders. 
The relative risk of breast cancer comparing metformin initiators to sulfonylureas 
initiators was initially examined with AT approach as the primary analyses, and then repeated 
with ITT approach as the secondary analyses. For each cohort, we calculated incidence rates of 
breast cancer per 100,000 person-years and use Kaplan-Meier methods to plot cumulative 
incidence of breast cancer. A Cox proportional regression models was used to estimate the crude 
and adjusted hazard ratios (HRs) of breast cancer and their corresponding 95% confidence 
intervals (CIs). The proportional hazard assumption was assessed by an addition of an interaction 
term between cohort and log survival time and by plotting –ln(ln(estimated survivor function)) as 
a function of time on the logarithmic scale. To explore the trend of hazard ratio over time, we 
further estimated hazard ratios for sequential 6-month intervals since treatment initiation. 
We also performed subgroup analyses for age, race/ethnicity and use of statin at initiation. 
It has been shown that subtype of breast cancer varies by age and race [48, 49]. African 
Americans are more likely to develop triple receptor-negative breast cancer than white women. 
Thus, age and race/ethnicity were likely to be effect modifiers on the association between 
metformin and breast cancer incidence. Statin, HMG-CoA reductase inhibitors, has been linked 
to reduce cancer incidence [50, 51]. Although clinical evidence suggests that statins does not 
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affect the incidence of breast cancer, a recent observational study of a large national cohort 
showed that statins may significantly improve cancer mortality after diagnosis of breast cancer 
[52]. Given the possible chemopreventive effect from statin on breast cancer, we evaluated the 
risk of breast cancer associated with metformin in strata based on presence or absence of statin 
prescription at baseline (i.e., defined in 6 months prior to treatment initiation). 
Several sensitivity analyses were pre-planned.  
(1) To evaluate the robustness of the assumptions of induction and latency periods made 
in the study, the main analysis was repeated with various lengths of time for the 
induction period ranging from 0 to 365 days and for the latency period ranging from 0 
to 730 days.  
(2) Six-month washout period may not be long enough to successfully capture new users 
and to accurately assess covariates at baseline. Thus, we repeated the study in which 
increases the washout period for new use and covariate assessment to 12 months.  
(3) Carcinoma in situ is an early form of cancer and is highly possible to transform into 
invasive cancer but not necessarily. Given greater clinical interests in invasive 
carcinoma than carcinoma in situ, we further restricted the outcome of interest to 
invasive breast cancer only.  
(4) To minimize the potential misclassification in defining treatment use during follow-
up and diabetic patients, we repeated the main study with a longer grace period of 180 
days and restricting to new users who had a diagnosis code for diabetes within 6 
months before initiation, respectively.  
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(5) Due to under-coding of renal disease, we conducted the analyses including prior renal 
disease and excluding only those patients with severe renal disease (i.e., chronic 
kidney disease stage 4 and 5).  
(6) Given the unresolved concerns that sulfonylureas may increase the risk of breast 
cancer, we also conducted sensitivity analyses of using two comparator groups: (1) 
new users of Thiazolidinediones (TZDs) or Incretins; (2) diabetic patients who started 
treatment of angiotensin-converting-enzyme inhibitors (ACE inhibitors) and did not 
receive any prescription of anti-diabetic drugs. ACE inhibitors were chosen because 
of the following reasons. First, the older persons have a high prevalence of 
hypertension.  Secondly, ACE inhibitors are considered as one of the first line 
treatment in hypertension. Patients starting treatments with ACE inhibitors are less 
likely to have severe hypertension, thus patient characteristics may not be heavily 
weighted in cardiovascular diseases, compared with metformin initiators. Lastly, 
hypertension is not a risk factor for breast cancer and no evidence shows that ACE 
inhibitors are associated with an altered risk of breast cancer. 
2. Analyses to address Specific Aim 1b (Unmeasured Variables) 
In this cross-sectional study, we calculated the prevalence of variables of interest by 
study cohort, and used a logistic regression model to estimate odds ratio (OR) of receiving 
metformin versus sulfonylureas and their corresponding 95% confidence intervals. Analysis was 
adjusted in a multivariable model, as described in the section of Confounding Control.  
The results from this validation study were used to calculate the extent of potential 
confounding by BMI and smoking status for our main analysis (Aim 1a: Breast Cancer Risk) and 
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to further correct the effect estimates in the main study using propensity score calibration 
(PSC).[53] In line with our main study (female cohort), we use data from women only in the 
validation study.  We quantified these associations independent of other covariates, fitting 
propensity score model equivalent to the one in the main study as far as possible (the number of 
initiators may limit the number of covariates that can be included in PS models in the validation 
study).   
To implement PSC, two PSs were estimated within the MCBS data: (1) the error-prone 
PS (PSEP, MCBS) based on the same variables used in the main study, and (2) the gold-standard PS 
(PSGS, MCBS) based on not only the same variables in the main study but also additional 
unmeasured variables (i.e., BMI and smoking status). We fit a model for the simple linear 
regression of PSGS, MCBS on PSEP, MCBS and treatment (Equation 3.1).  Then, based on the 
estimated parameters from this model, we imputed a new PS (considered as “Gold-standard”, 
PSGS, main) with the original PS (considered as “error-prone”, PSEP, main) in the main study.  The 
association of metformin-breast cancer was estimated in a Cox model, adjusted by SMR 
weighting.  
𝑃𝑆𝐺𝑆 = 𝛽0 + 𝛽1(𝑃𝑆𝐸𝑃) + 𝛽2(𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)                                                         (Equation 3.1) 
3. Analyses to address Specific Aim 2 (Screening Mammography) 
In the new user cohort, we began with a description of metformin and sulfonylureas 
initiators by receipt of screening mammography during a two-year window of 12 months pre- 
and post-initiation. The day of initiation was indexed as Month 0, and was included in the month 
following initiation (Month 1). Frequency of initiators receiving a screening mammogram was 
summarized within sequential 3-month and 12-month intervals from Month -12 (before initiation) 
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to Month 12 (after initiation), respectively. Plots of frequency by time interval were used to 
visually compare the temporal trends of each event by treatment. Incident breast cancer detected 
at screening was calculated over 12-monthly intervals, given expected small numbers. We 
estimated risks and risk differences (RDs) and their 95% CIs of each event during each time 
interval comparing metformin to sulfonylureas initiators.   
In the cancer-free study, we repeated all analyses during the time window of 12 months 
after initiation only and calculated RD of total breast cancer incidence comparing metformin to 
sulfonylureas groups in 12 months after initiation. Given the fact that screening mammography 
prior to initiation is likely associated with receiving subsequent screening tests after initiation, 
we additionally included the variable of prior screening in the propensity score model for 
confounding control. Furthermore, the analyses in this cancer-free cohort were stratified by 
receipt of screening mammography in 12 months prior to initiation. 
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CHAPTER 4. BREAST CANCER RISK IN OLDER WOMEN INITIATING 
METFORMIN VERSUS SULFONYLUREAS  
I. Introduction 
Breast cancer is the most common cancer and is the second leading cause of cancer death 
for women in the United States . The cost of breast cancer care in 2010 was estimated at 16.5 
billion dollars in US, the highest among all cancer sites [55]. Diabetes increases breast cancer 
risk by 20-40% in women [56]. As the first-line treatment for type 2 diabetes [10], metformin has 
received much attention due to its potential beneficial effect on cancer incidence and outcomes, 
in particular, on breast cancer [20-22].  
Evidence from preclinical and clinical studies suggests that metformin has anti-tumor 
properties and may reduce incidence and mortality of breast cancer [23, 24]. A meta-analysis of 
seven observational studies found a 17% decreased risk of breast cancer associated with 
metformin, and reported that metformin use for 3 years or longer reduced the risk of breast 
cancer by 25% [6]. Despite several observational studies indicating chemopreventive effects of 
metformin on breast cancer, concerns have been raised that many of these studies were subject to 
time-related biases (e.g., immortal time bias and time-window bias) which would lead to an 
apparent protective effect in the absence of a real effect or magnify any potential beneficial 
effect of metformin on cancer incidence [7].  
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Body mass index (BMI) and smoking may confound the metformin-breast cancer 
association, but were rarely assessed in previous studies. BMI and smoking are risk factors 
forbreast cancer in postmenopausal women [34, 36, 58]. Given weight loss and potential anti-
cancer benefits of metformin, physicians may preferably prescribe metformin to overweight or 
obese patients, as well as smokers. Thus, unmeasured confounding by BMI and smoking is of 
concern and merits investigation although it would not lead to a spurious protective effect.  
Observational studies are useful to evaluate drug safety and effectiveness in real world 
setting, as well as for hypothesis generation [59, 60]. If incorrectly designed, however, they can 
suffer from various types of biases leading to spurious results. For example, observational 
findings on benefits of statins in patients with COPD were recently disproved by a randomized 
trial [61]. The discordance between observational studies and randomized trials is often 
portrayed as being the results of a fatal flaw inherent to observational studies, but such a view 
ignores the fact that not all observational studies are created equal. Observational studies need to 
be designed using rigorous methods to reduce the potential for bias. Our objective was to 
investigate whether metformin reduces the risk of breast cancer in a large, nationally 
representative older population in the US, by conducting a state-of-the art new user cohort study 
with an active comparator. 
II. Methods 
Study Population 
We included women aged 65 years or older with continuous enrollment in Medicare Parts 
A, B, and D fee-for-service coverage and no managed care coverage for ≥6 months during the 
period from 2007 to 2011 and who newly initiated treatment with metformin or sulfonylureas. 
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Initiation was defined as not receiving any anti-diabetic treatment within 6 months prior to 
initiation of monotherapy with metformin or sulfonylureas and having ≥1 refill within 90 days 
after the end of days-supply of the first prescription. The date of the first refill was defined as the 
index date. Patients were excluded if they had a prior diagnosis of renal disease or cancer during 
the 6 months before the index date. Patients with renal disease were excluded because metformin 
is contraindicated in these patients [10]. The flowchart of study population is shown in Figure 
4.1. 
Follow-up for Breast Cancer 
The outcome of interest was a diagnosis of incident breast cancer during follow-up, 
including both in situ and invasive breast cancer, identified by having at least two ICD-9 
diagnosis codes for breast cancer on different dates within 60 days.  The date of the first 
diagnosis was used to define the outcome date. This algorithm has been previously validated in a 
Medicare population [44]. 
We used both as-treated (AT; primary) and intention-to-treat (ITT; secondary) analyses. 
Because breast cancer has a long preclinical phase, we assumed a 180-day induction period for 
cancer pathogenesis and a 180-day carry-over effect or latency period for cancer detection in the 
analysis. In the AT approach, follow-up started on 180 days after the index date, and ended with 
the earliest of the following events: 180 days (latency period) after treatment change or 
discontinuation, any cancer diagnosis except for non-melanoma skin cancer, death, enrollment 
gap in Medicare part ABD enrollment greater than 1 month, or end of study (December 31st, 
2011). Treatment change was defined as a subsequent addition of or switch to other anti-diabetic 
drug classes to the index prescription. Treatment discontinuation was defined as no further refill 
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within the days of supply plus a 90-day grace period. Secondly, the ITT analysis followed 
patients from 180 days after the index date and until the date of any cancer diagnosis except for 
non-melanoma skin cancer, death, or end of study, irrespective of any treatment change or 
discontinuation. 
Confounding control 
We used propensity scores (PSs) to control measured confounding [46]. For each patient, 
the probability of receiving metformin vs sulfonylureas was estimated using a logistic regression 
model, which included demographic and clinical variables that we identified as potential 
confounders or risk factors for breast cancer. All covariates were defined based on available 
information during the 6-month period prior to initiation. We standardized the distribution of 
these covariates to that of  the metformin initiators using weights of 1 for metformin initiators 
and the odds of PS for sulfonylureas initiators [47]. 
Statistical Analysis 
Baseline characteristics were summarized by study cohort and were further adjusted by 
PS weighting. For each cohort, we used Kaplan-Meier methods to plot cumulative incidence and 
Poisson regression models to estimate the crude and weighted incidence rates for breast cancer. 
We then used a Cox proportional regression model to estimate the crude and weighted hazard 
ratios (HRs) of breast cancer with 95% confidence intervals (CIs) using a robust variance 
estimation for the weighted model. To explore potential trends of the HRs over time, we 
estimated HRs in sequential 6-month intervals since the index date. We also performed subgroup 
analyses, stratified by age group, race, and baseline use of statins.  
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Several sensitivity analyses were pre-planned. First, given the unresolved concerns 
whether sulfonylureas have effect on breast cancer risk, we compared the risk of breast cancer in 
new users of metformin vs two different active comparator groups: (1) new users of 
thiazolidinediones (TZDs) or incretins, both of which are also oral hypoglycemic agents; (2) 
diabetic patients who initiated angiotensin-converting-enzyme inhibitors (ACEI) without prior 
use of any anti-diabetic drugs. Secondly, to minimize the potential misclassification in defining 
treatment use during follow-up and diabetic patients, we repeated the main study with a longer 
grace period of 180 days and restricting to new users who had a diagnosis code for diabetes 
within 6 months before initiation, respectively. Due to undercoding of renal disease, we 
conducted the analyses including prior renal disease and excluding only those patients with 
severe renal disease (i.e., chronic kidney disease stage 4 and 5). Additionally, we restricted the 
outcome of interest to invasive breast cancer only. Lastly, to evaluate the robustness of the 
assumptions of induction and latency periods, the main analysis was repeated while varying the 
induction period from 0 to 365 days (for both AT and ITT analysis) and the latency period from 
0 to 730 days (for AT analysis).  
External Validation Study 
To quantify the extent of residual confounding by BMI and smoking that are unavailable 
in Medicare claims, we conducted a cross-sectional study using external data from the MCBS 
2006-2009 panels to identify women initiating metformin or sulfonylureas.  New use was 
defined as initiation of monotherapy with metformin or sulfonylureas after at least 6 months 
without a prescription for metformin or sulfonylureas. Given the sample size of the MCBS is 
relatively modest and therefore that the absolute number of women initiating these drugs is small 
in the MCBS, initiation was defined by requiring only one prescription. We extracted data on 
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height, weight, and self-reported smoking status from the MCBS Cost & Use module in the same 
year of initiation. BMI was calculated by weight (kilogram) divided by height (meter) squared, 
and was treated as a continuous variable as well as a categorical variable (<25 as normal; ≥25 
and <30 as overweight; and ≥30 as obese) .  Individual smoking status was grouped into never 
and ever smoker. History of comorbidity and co-medication at baseline were retrieved from the 
linked Medicare claims data.  
We used multivariable logistic regression models to estimate odds ratios (ORs) for the 
association of BMI and smoking with the initiation of metformin vs sulfonylureas, controlling 
for those covariates also controlled for in the main study. We then implemented propensity score 
calibration (PSC) to correct the effect estimates in the Medicare study for confounding by BMI 
and smoking [53, 62]. 
III. Results 
We identified 36,367 and 11,730 women who initiated metformin or sulfonylureas who 
met our inclusion criteria, respectively. Compared with metformin initiators, sulfonylureas 
initiators were older, had more cardiovascular disease (i.e., congestive heart failure and ischemic 
heart disease), and were more likely to have been admitted to a hospital and visited an 
emergency room in the 6 months prior to the index date (Table 4.1). Metformin initiators were 
more likely to have received a prescription for statins, a mammogram or a lipid test compared 
with sulfonylureas initiators. The characteristics of the women initiating sulfonylureas became 
very similar to those initiating metformin after PS weighting.   
In our primary, AT analysis, 338 patients were diagnosed with breast cancer over 53,271 
person-years of follow-up: 262 cases were among metformin initiators and 76 cases were in 
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sulfonylureas initiators (Table 4.2). The crude incidence rates of breast cancer per 100,000 
person-years were 640 (95% CI: 567 to 723) and 615 (95% CI: 491 to 771) in metformin and 
sulfonylureas initiators, respectively. After PS weighting, the incidence rate was 607 (95% CI: 
549 to 670) in sulfonylureas initiators and stayed the same in metformin initiators. The weighted 
HR comparing metformin with sulfonylureas initiators was 1.08 (95% CI: 0.81 to 1.44) (Table 2). 
The effect estimate from the ITT analysis was unchanged (adjusted HR: 1.08; 95% CI: 0.86 to 
1.35). There was no difference in the cumulative incidence of developing breast cancer by 
treatment group (Figure 4.2). In Figure 4.3, we examined the risk of breast cancer associated 
with metformin stratified by duration of treatment after initiation. No decreasing trend was 
observed after initiation and HR estimates were all close to the null.  
Figure 4.4 shows the breast cancer risk for metformin vs sulfonylureas initiators across 
several subgroups. There was no indication of a protective effect across the age groups and in 
either subgroup defined by prior statin use. However, we observed a possibly reduced risk for 
breast cancer associated with metformin in African American women (HR: 0.61; 95% CI: 0.30 to 
1.25, for AT) but the confidence interval is wide due to the small number of events.  The results 
were similar in the AT and ITT analyses. We also conducted several sensitivity analyses, 
showing that metformin was not associated with a lower risk of breast cancer consistently 
through all scenarios (Tables 4.3, 4.4 and 4.5). 
We further controlled for unmeasured confounding by BMI and smoking with PSC. A 
total of 118 and 79 female initiators of metformin and sulfonylureas were identified from the 
MCBS. Being obese (BMI: ≥30) and ever smokers were associated with metformin initiation 
(Table 4.6). These associations were diluted after multivariable adjustment (mainly because of 
age effects), indicating little difference in BMI and smoking status conditional on controlling for 
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other differences. After PSC, the HR for breast cancer comparing metformin vs sulfonylureas 
was 1.05 (95% CI: 0.80 to 1.39) and 1.05 (95% CI: 0.84 to 1.30) based on AT and ITT analyses, 
respectively. 
IV. Discussion and Conclusions 
In this large, population-based study using a state-of-the art new user, active comparator 
cohort design we found that older women initiating metformin did not have a lower risk for 
breast cancer than women initiating a therapeutic alternative. Similar results were observed when 
comparing metformin initiators to initiators of TZD/incretin or to diabetic initiators of ACEI. 
Despite our observation of a possible tendency towards a lower risk of breast cancer associated 
with metformin in African American women, our result of no effect was consistent across 
several subgroup and sensitivity analyses.   
A meta-analysis found a decreased risk of breast cancer associated with metformin (OR: 
0.83; 95% CI: 0.71 to 0.97) and a stronger association with longer metformin use (>3 years) (OR: 
0.75; 95% CI: 0.62 to 0.91), subsequently supported by another meta-analysis (OR: 0.94; 95% 
CI: 0.91 to 0.99) [6, 33]. However, Suissa and Azoulay have pointed out that many of the studies 
included in the meta-analysis were affected by time-related biases, including immortal time bias, 
time-window bias, and time-lag bias [7]. In both meta-analyses, for example, the beneficial 
effect of metformin on breast cancer risk was mainly driven by the case-control study based on 
data from the Clinical Practice Research Datalink (CPRD), showing that the long-term use of 
metformin (≥ 40 prescriptions) had a strong effect on preventing breast cancer, compared with 
no use of metformin (OR: 0.42; 95% CI: 0.21 to 0.87) [1]. This apparent protective effect is 
likely due to time-window bias, which results from unequal lengths of follow-up time between 
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cases and controls to define exposure because cases and controls were not matched on time since 
onset of diabetes or since the first antidiabetic prescription in this study [63]. Among those 
studies not affected by time-related bias, the findings were controversial: two studies reported 
protective effects [3, 5] while two reported no effects [29, 30]. In a cohort study from the 
Netherlands, the risk of breast cancer slightly decreased in new users of metformin compared 
with new users of sulfonylureas (HR: 0.95; 95% CI: 0.91 to 0.98) [5]. This study included 
women age 18 or older, a younger study population than ours. Metformin might act differently 
on breast cancer between pre- and post-menopausal women. The Women Health Initiative (WHI) 
study found a reduced risk of invasive breast cancer associated with metformin in post-
menopausal women (HR: 0.75; 95% CI: 0.57 to 0.99) [3]. Drug exposure in the WHI study was 
self-reported and collected through questionnaire with unequal intervals whereas our study used 
data on pharmacy dispensed prescriptions that provide more accurate drug exposure information. 
Two cohort studies showed evidence of no effect of metformin versus sulfonylureas risk of 
breast cancer in the UK CPRD (HR: 1.04; 95% CI: 0.79 to 1.37 [30], HR: 1.04; 95% CI: 0.83 to 
1.31 [29]).  
Our findings suggest that metformin may be associated with a lower risk of breast cancer 
among African American women, although this association was not statistically significant. 
African Americans are more likely to develop triple receptor-negative breast cancer (TNBC) 
than white women [48, 49].  One cohort study of 130 patients with TNBC found that use of 
metformin was associated a lower risk of distant metastases (HR: 0.61; 95% CI: 0.33 to 1.15) 
[64], supported by preclinical studies [65, 66]. One plausible explanation for these findings is 
that metformin may have a favorable effect on TNBC which is more prevalent in African 
Americans. In the WHI study, metformin use was associated with a greater reduced risk of breast 
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cancer negative for HER2 overexpression (HR: 0.58; 95% CI: 0.40 to 0.84), compared with 
overall invasive breast cancer (HR: 0.75; 95% CI: 0.57 to 0.99), despite the fact that the two CIs 
overlapped [3]. Our subgroup analysis is limited by the small number of breast cancers in 
African American women observed, thus chance is a plausible alternative explanation.  
We used external information from the MCBS to quantify the unmeasured confounding 
by BMI and smoking on the association between metformin and breast cancer incidence. Obesity 
and smoking were associated with higher odds of receiving metformin vs sulfonylureas. 
However, these associations became weak after adjusting for other variables in the PS model, 
indicating a little independent effect of BMI and smoking of metformin prescribing relative to 
sulfonylureas and little residual confounding by BMI and smoking on the association between 
metformin and breast cancer incidence. This lack of effect on relative prescribing given the 
indication to initiate treatment with oral anti-diabetics is a direct result of the state-of-the art new 
user, active comparator cohort design [67]. We consistently observed no metformin-breast 
cancer associations after implementing PSC. 
Our study has limitations. It is limited by the short follow-up time (up to 4.5 years). 
Diabetes treatment regimens are usually modified over time for adequate glycemic control as 
diabetes progresses, so the observed duration on the initial treatment is limited by actual 
treatment dynamics (median: 0.79 year; IQR: 0.35 to 1.65) in the AT analysis. In the ITT 
analysis which ignored treatment changes during follow-up, the follow-up time was almost 
double (median: 1.53 years; IQR: 0.69 to 2.56), but still short for evaluating a cancer outcome. 
We thus cannot exclude the possibility of a beneficial effect of long-term use of metformin on 
breast cancer risk. Due to a relative short period (180 days) of assessment of prior drug use and 
covariates, our study population may include some patients with prior treatment or prevalent 
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breast cancer, but we would not expect this to be differential between metformin and 
sulfonylureas groups. In addition, confounding by unmeasured variables may still exist. We 
examined the impact of two major unmeasured confounders, BMI and smoking, however, 
suggesting little residual confounding. Unmeasured confounding by e.g., alcohol consumption or 
family history of breast cancer would need to be independent of the other covariates that we 
controlled for. Lastly, we did not independently validate the diagnoses of breast cancer, but our 
algorithm based on ICD-9 codes has been validated with cancer registry data in an, albeit 
selected, Medicare population [44].  
In conclusion, our findings suggest that metformin does not reduce the risk for breast 
cancer among women aged 65 years or older. We acknowledge that this study was limited by a 
short treatment and follow-up time, the former mainly a function of real-world treatment 
dynamics. Randomized clinical trials have been initiated to evaluate metformin’s benefit on 
cancer incidence and outcomes and will provide more definitive answers; however, this approach 
may not represent the optimal use of scarce resources, given that the observational evidence 
leading to these trials likely suffered from avoidable biases. 
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V. Tables and Figures 
TABLE 4.1. Characteristics in New Users of Metformin and Sulfonylureas at Baseline 
Characteristics Metformin Sulfonylureas 
Weighted 
Sulfonylureas* 
Total    36367  (100.0)    11730  (100.0) (100.0) 
Median of Age  
(IQR) 
72.0 
(68.0-78.0) 
76.0 
(70.0-84.0) 
72 
(67.0-78.0) 
Race       
     White    13249  (36.4)     2931  (25.0) (37.2) 
     African American     9393  (25.8)     2109  (18.0) (23.7) 
     Others     6395  (17.6)     2056  (17.5) (17.2) 
Comorbidity       
Benign Breast Disease     1284  (3.5)      290  (2.5) (3.3) 
Benign neoplasm of breast       55  (0.2)       15  (0.1) (0.1) 
COPD     2737  (7.5)     1136  (9.7) (8.0) 
Congestive Heart Failure     3199  (8.8)     2036  (17.4) (9.2) 
Ischemic Heart Disease     6522  (17.9)     2987  (25.5) (18.4) 
Hypertension    28332  (77.9)     9139  (77.9) (77.9) 
Osteoporosis     4069  (11.2)     1259  (10.7) (11.3) 
Medications       
Estrogen     2232  (6.1)      491  (4.2) (5.9) 
Progestin      262  (0.7)       45  (0.4) (0.7) 
Statins    20268  (55.7)     5413  (46.1) (55.2) 
Bisphosphonates     4384  (12.1)     1184  (10.1) (12.2) 
ACE Inhibitors    13715  (37.7)     4354  (37.1) (37.7) 
ARBs     7762  (21.3)     2253  (19.2) (21.6) 
Beta Blockers    14412  (39.6)     4978  (42.4) (39.6) 
Antidepressants    10313  (28.4)     3385  (28.9) (28.5) 
Digoxin     1682  (4.6)      998  (8.5) (4.8) 
Calcium Channel Blockers    10479  (28.8)     3676  (31.3) (29.1) 
Loop Diuretics     5703  (15.7)     2987  (25.5) (16.2) 
Non-Loop Diuretics    14747  (40.6)     3968  (33.8) (39.9) 
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TABLE 4.1. (Continued) Characteristics in New Users of Metformin and Sulfonylureas 
at Baseline 
Characteristics Metformin Sulfonylureas 
Weighted 
Sulfonylureas* 
Health Care Use       
Days of hospitalization       
Mean (SD) 0.8  (4.2) 1.6  (5.8) 0.9 (8.0) 
Category       
0    32421  (89.1)     9544  (81.4) (88.7) 
1 to 7     2859  (7.9)     1408  (12.0) (8.2) 
7 to 14      577  (1.6)      434  (3.7) (1.7) 
>14      510  (1.4)      344  (2.9) (1.5) 
Number of ER Visit       
0    29544  (81.2)     8596  (73.3) (80.9) 
1     4694  (12.9)     1990  (17.0) (12.9) 
2+     2129  (5.9)     1144  (9.8) (6.2) 
Number of Physician Visit       
0     2462  (6.8)     1237  (10.5) (7.1) 
1-3     9115  (25.1)     3073  (26.2) (25.4) 
4-6     9118  (25.1)     2729  (23.3) (24.8) 
7-12     9794  (26.9)     2976  (25.4) (26.4) 
13+     5878  (16.2)     1715  (14.6) (16.3) 
Mammography     7334  (20.2)     1526  (13.0) (20.0) 
Lipid Test    24905  (68.5)     6439  (54.9) (67.7) 
Abbreviation: IQR: Interquartile Range; ACE inhibitor: angiotensin-converting-enzyme inhibitor; ARB: 
angiotensin receptor blockers; COPD: Chronic Obstructive Pulmonary Disease; ER: Emergency Room. 
* Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin 
initiators and the odds of the estimated PS for sulfonylureas initiators. PS model includes age in years 
(continuous variable), race (white, black, and others), comorbidity (Yes/No; benign breast disease, benign 
neoplasma of breast, chronic obstructive pulmonary disease, chronic heart failure, chronic kidney disease, 
acute kidney injury, ischemic heart disease, hypertension, and osteoporosis), medication use (Yes/No; 
estrogen, progestin, statins, bisphosphonates, ACE inhibitors, ARBs, beta blockers, antidepressant, digoxin, 
calcium channel clockers, loop diuretics, and non-loop diuretics), and healthcare utilization (days of 
hospitalization (continuous variable), number of physician visit (categorical variable), number of emergency 
room visit (categorical variable), mammograms (Yes/No), and lipid tests (Yes/No)).  
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TABLE 4.2. Incidence Rates and Hazard Ratios for Breast Cancer by Treatment Cohort 
Cohort N 
BC 
event 
Follow-up Time (years) Rate per 100,000 pyrs
†
 HR (95% CI) 
Sum Median (IQR) Crude PS Weighted* Crude PS Weighted* 
As-Treated Analysis 
MET 36367 262 40921 0.80 (0.36-1.68) 640 (567-723) 640 (567-723) 1.04 (0.81-1.34) 1.08 (0.81-1.44) 
SUL 11730 76 12350 0.73 (0.33-1.55) 615 (491-771) 607 (549-670) 1.00   1.00 
Intention-to-Treat Analysis 
MET 36367 395 60311 1.51 (0.68-2.54) 655 (593-723) 655 (593-723) 1.04 (0.85-1.27) 1.08 (0.86-1.35) 
SUL 11730 127 20154 1.60 (0.70-2.63) 630 (530-750) 592 (519-675) 1.00   1.00 
Abbreviation: MET: metformin; SUL: sulfonylureas; BC: breast cancer; IQR: Interquartile Range; pyrs: person-years; PS: propensity score. 
*PS weighted HR were standardized to the distribution of baseline covariates in metformin initiators 
† Based on Surveillance, Epidemiology, and End Results Program (SEER) 2007-2011 data, the incidence rate of breast cancer for women aged 65 and over 
women is 420.5 cases per 100,000 person-years . We observed approximately 1.5-fold incidence rate of breast cancer in the initiators of metformin and 
sulfonylureas, likely explained by the diabetic study population in our study.  
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TABLE 4.3. Sensitivity Analyses 
Sensitivity Analysis Analysis Cohort N 
BC 
event 
Median of 
Follow-up years 
(IQR) 
Rate per 100,000 
person-years 
PS Weighted HR 
(95% CI)* 
Using initiators of 
TZD/Incretin as reference 
ITT 
MET 36397 395 1.51 (0.68-2.54) 655 (593-722) 1.08 (0.78-1.49) 
TZD/DPP 4533 48 1.72 (0.75-2.77) 592 (446-786) 1.00 
AT 
MET 36397 262 0.80 (0.36-1.68) 640 (567-722) 0.91 (0.60-1.38) 
TZD/DPP 4533 27 0.61 (0.33-1.33) 629 (431-917) 1.00 
Using diabetic initiators 
of ACEI as reference 
ITT 
MET 18913 201 1.52 (0.69-2.55) 639 (557-734) 1.00 (0.79-1.26) 
ACEI 20583 209 1.58 (0.73-2.57) 598 (522-685) 1.00 
AT 
MET 18913 114 0.68 (0.33-1.43) 608 (506-731) 0.96 (0.69-1.32) 
ACEI 20583 117 0.70 (0.34-1.48) 549 (458-657) 1.00 
Initiators with a prior DM 
diagnosis 
ITT 
MET 32450 335 1.53 (0.70-2.56) 619 (556-689) 1.03 (0.81-1.29) 
SUL 10925 119 1.63 (0.72-2.66) 629 (525-753) 1.00 
AT 
MET 32450 222 0.81 (0.36-1.69) 604 (530-689) 1.03 (0.77-1.39) 
SUL 10925 72 0.74 (0.33-1.57) 622 (493-783) 1.00 
Outcome including 
invasive breast cancer 
only 
ITT 
MET 36442 390 1.52 (0.69-2.55) 643 (583-711) 1.05 (0.84-1.32) 
SUL 11761 128 1.61 (0.71-2.64) 632 (531-751) 1.00 
AT 
MET 36442 260 0.81 (0.36-1.68) 632 (560-714) 1.05 (0.79-1.40) 
SUL 11761 78 0.73 (0.33-1.56) 629 (504-785) 1.00 
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TABLE 4.3. (Continued) Sensitivity Analyses 
Sensitivity Analysis Analysis Cohort N 
BC 
event 
Median of 
Follow-up years 
(IQR) 
Rate per 100,000 
person-years 
PS Weighted HR 
(95% CI)* 
Including patients with or 
without history of renal 
disease 
ITT 
MET 38435 405 1.51 (0.68-2.53) 638 (578-703) 1.06 (0.86-1.31) 
SUL 14558 149 1.53 (0.66-2.57) 611 (520-718) 1.00 
AT 
MET 38435 269 0.80 (0.35-1.66) 627 (557-707) 1.12 (0.85-1.47) 
SUL 14558 87 0.70 (0.33-1.50) 581 (471-717) 1.00 
Excluding patients with 
history of chronic kidney 
disease stage 4-5 
ITT MET 38251 404 1.51 (0.68-2.54) 639 (579-704) 1.05 (0.85-1.30) 
SUL 13803 144 1.54 (0.67-2.59) 619 (526-729) 1.00 
AT 
MET 38251 269 0.80 (0.35-1.66) 629 (558-709) 1.09 (0.83-1.43) 
SUL 13803 85 0.71 (0.33-1.51) 595 (481-736) 1.00 
Grace Period of 180 days 
ITT 
MET 36387 397 1.51 (0.68-2.55) 657 (595-725) 1.09 (0.87-1.37) 
SUL 11460 123 1.62 (0.71-2.66) 621 (520-741) 1.00 
AT 
MET 36387 301 0.96 (0.44-1.87) 667 (596-747) 1.20 (0.90-1.59) 
SUL 11460 79 0.86 (0.38-1.75) 594 (477-741) 1.00 
Abbreviation: AT: as-treated; ITT: intention-to-treat; MET: metformin; SUL: sulfonylureas; TZD:  Thiazolidinediones; ACEI: angiotensin-converting-enzyme 
inhibitors; BC: breast cancer; IQR: Interquartile Range; pyrs: person-years; PS: propensity score. 
* Propensity score (PS) was re-estimated based on the same model for each sensitivity analysis. 
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TABLE 4.4. Sensitivity Analyses for Induction and Latency Periods in As-Treated 
Analysis 
Induction 
Period 
(days) 
Latency 
Period 
(days) 
Cohort N 
BC 
event 
Median of 
Follow-up years 
(IQR) 
Rate per 100,000 
pyrs 
PS Weighted 
HR (95% CI)* 
0 0 
MET 43427 414 0.84 (0.40-1.77) 791 (718-871) 1.16 (0.92-1.47) 
SUL 13958 107 0.75 (0.33-1.63) 689 (570-832) 1.00  
90 0 
MET 37336 304 0.78 (0.29-1.72) 716 (640-802) 1.19 (0.90-1.58) 
SUL 11593 77 0.71 (0.27-1.61) 620 (496-775) 1.00  
180 0 
MET 29404 222 0.87 (0.33-1.80) 650 (570-741) 1.10 (0.80-1.52) 
SUL 8947 60 0.79 (0.30-1.69) 607 (471-782) 1.00  
360 0 
MET 19067 144 0.93 (0.41-1.79) 650 (552-765) 1.15 (0.77-1.73) 
SUL 5566 37 0.90 (0.38-1.73) 588 (426-811) 1.00  
0 90 
MET 43427 441 0.96 (0.57-1.85) 778 (709-854) 1.14 (0.91-1.43) 
SUL 13958 117 0.89 (0.51-1.74) 681 (568-816) 1.00  
90 90 
MET 39745 328 0.82 (0.39-1.72) 706 (634-787) 1.17 (0.89-1.52) 
SUL 12813 86 0.73 (0.33-1.59) 619 (501-764) 1.00  
180 90 
MET 34168 240 0.77 (0.28-1.68) 642 (566-729) 1.12 (0.82-1.52) 
SUL 10616 65 0.70 (0.26-1.57) 589 (462-751) 1.00  
360 90 
MET 20883 154 0.90 (0.38-1.75) 649 (554-760) 1.16 (0.78-1.72) 
SUL 6253 40 0.87 (0.35-1.69) 583 (428-795) 1.00  
0 180 
MET 43427 466 1.08 (0.66-1.93) 770 (703-843) 1.13 (0.91-1.40) 
SUL 13958 128 1.03 (0.63-1.83) 686 (577-815) 1.00  
90 180 
MET 39745 353 0.95 (0.55-1.80) 702 (632-779) 1.14 (0.89-1.47) 
SUL 12813 97 0.87 (0.50-1.68) 631 (517-770) 1.00  
180 180 
MET 36367 262 0.80 (0.36-1.68) 640 (567-723) 1.08 (0.81-1.44) 
SUL 11730 76 0.73 (0.33-1.55) 615 (491-771) 1.00  
360 180 
MET 23320 161 0.85 (0.35-1.69) 629 (539-734) 1.08 (0.75-1.56) 
SUL 7178 47 0.80 (0.32-1.63) 623 (468-829) 1.00  
0 360 
MET 43427 510 1.38 (0.76-2.12) 761 (698-830) 1.18 (0.96-1.46) 
SUL 13958 137 1.34 (0.79-2.06) 647 (547-764) 1.00  
90 360 
MET 39745 397 1.23 (0.70-1.99) 699 (634-771) 1.21 (0.96-1.54) 
SUL 12813 106 1.19 (0.73-1.91) 592 (490-717) 1.00  
180 360 
MET 36367 306 1.05 (0.61-1.85) 646 (577-722) 1.18 (0.90-1.54) 
SUL 11730 85 1.02 (0.59-1.77) 572 (462-707) 1.00  
360 360 
MET 29200 196 0.78 (0.37-1.58) 636 (553-732) 1.26 (0.90-1.77) 
SUL 9507 52 0.74 (0.33-1.50) 548 (418-720) 1.00  
0 720 
MET 43427 567 1.68 (0.76-2.51) 754 (694-818) 1.12 (0.92-1.36) 
SUL 13958 166 1.77 (0.79-2.54) 678 (582-789) 1.00  
90 720 
MET 39745 454 1.60 (0.70-2.35) 699 (637-766) 1.13 (0.91-1.40) 
SUL 12813 135 1.66 (0.73-2.37) 637 (538-754) 1.00  
180 720 
MET 36367 363 1.51 (0.68-2.18) 653 (589-724) 1.09 (0.86-1.37) 
SUL 11730 114 1.55 (0.70-2.20) 627 (522-754) 1.00  
360 720 
MET 29200 253 1.29 (0.66-1.86) 649 (573-734) 1.09 (0.83-1.44) 
SUL 9507 81 1.31 (0.72-1.85) 634 (510-788) 1.00  
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TABLE 4.5. Sensitivity Analyses for Induction Periods in Intention-to-Treat Analysis 
Induction 
Period 
(days) 
Cohort N 
BC 
event 
Median of  
Follow-up years 
(IQR) 
Rate per 100,000 
pyrs 
PS Weighted HR 
(95% CI)* 
0 
MET 43427 599 1.68 (0.76-2.83) 749 (692-812) 1.11 (0.92-1.34) 
SUL 13958 179 1.77 (0.79-2.90) 676 (584-783) 1.00  
90 
MET 39745 486 1.60 (0.70-2.66) 697 (638-762) 1.12 (0.91-1.37) 
SUL 12813 148 1.66 (0.73-2.76) 638 (543-750) 1.00  
180 
MET 36367 395 1.51 (0.68-2.54) 655 (593-723) 1.08 (0.86-1.35) 
SUL 11730 127 1.60 (0.70-2.63) 630 (530-750) 1.00  
360 
MET 29200 285 1.41 (0.66-2.30) 652 (580-732) 1.08 (0.83-1.40) 
SUL 9507 94 1.51 (0.72-2.38) 636 (520-779) 1.00  
Abbreviation:  MET: metformin; SUL: sulfonylureas; BC: breast cancer; IQR: Interquartile Range; pyrs: 
person-years; PS: propensity score. 
*Propensity score (PS) was re-estimated based on the same model for each sensitivity analysis 
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TABLE 4.6. Characteristics in Metformin and Sulfonylureas at Baseline in the MCBS 2006-2009 
Characteristics MET SUL Crude OR (95% CI) Adjusted OR (95% CI)
#
 
Total 118 (100.0) 79 (100.0)   
Median Age (IQR) 74.0 (70.0-80.0) 78.0 (75.0-84.0) 0.92 (0.88-0.96)
$
 0.94 (0.89, 0.99) 
Race     
        White 89 (75.4) 59 (74.7) 1.04 (0.54-2.01) 0.85 (0.40, 1.82) 
        Other 29 (24.6) 20 (25.3) 1.00 1.00 
     
Median of BMI (IQR) 29.9 (25.6-34.0) 28.6 (25.1-33.1) 
1.01 (0.97-1.06)
$
 -- 
Mean of BMI (SD) 30.5 (6.5) 29.9 (6.9) 
BMI Category*     
<25 24 (20.3) 18 (22.8) 1.00 1.00 
25 to <30 35 (29.7) 30 (38.0) 0.87 (0.40-1.91) 0.84 (0.34, 2.06) 
≥30 58 (49.2) 29 (36.7) 1.50 (0.70-3.20) 1.27 (0.52, 3.10) 
Smoking Status*     
Never 61 (51.7) 48 (60.8) 1.00 1.00 
Ever Smoking 57 (48.3) 28 (35.4) 1.60 (0.89-2.89) 1.41 (0.72, 2.74) 
Abbreviation: MET: metformin initiators; SUL: sulfonylureas initiators; IQR: interquartile range; SD: standard deviation 
* Missing data on BMI and Smoking status were less than 5%. Our DUA does not allow us to present cell sizes <11, so the number of missing was not 
presented on this table. 
$ OR for 1 unit increase 
# Adjusted OR was controlled for BMI (categorical), smoking status (never and ever), age, race (white and others), congestive heart failure, ischemic heart 
disease, beta blocker, anti-hypertensive drugs, loop diuretics, mammogram, admission to hospital, and physician visit in the PS model, as known as gold-
standard PS in PSC method.  
† To implement PSC, two PSs were estimated within the MCBS data: the error-prone PS (PSEP, MCBS) based on covariates available in claims, and the gold-
standard PS (PSGS, MCBS) based on BMI and smoking status in addition to the variables available in claims. We fit a model for the simple linear regression 
of PSGS, MCBS on PSEP, MCBS and treatment.  Then, based on the estimated parameters from this model, we imputed a new PS (considered as “Gold-
standard”, PSGS, Medicare) with the original PS (considered as “error-prone”, PSEP, Medicare) and treatment in the main study.  The association of metformin-
breast cancer was estimated in a Cox model, weighted by imputed PSGS, Medicare. We acknowledge that the surrogacy assumption for PSC may be violated 
in our study, but we were not able to test this assumption due to lack of outcome information in the MCBS. However, our results showed a little residual 
unmeasured confounding by BMI and smoking, thus leading to an unbiased PSC.  
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Medicare enrollee’s with at least 6-month  
Part A, B, and D fee-for-service coverage 
between 2007 and 2011 
Patients who initiated metformin with 
prior 6-month washout period 
(N=148,855) 
Patients who initiated sulfonylureas with 
prior 6-month washout period 
(N=100,237) 
Excluded patients without a refill or with 
prior use of any other anti-diabetic drugs 
Eligible New Users of Metformin  
(N=53,558) 
* Date of the first refill was defined as 
the index date  
New Users of Metformin  
(N=43,462)  
Final Cohort: New Users of Metformin 
(N=36,367)  
Eligible New Users of Sulfonylureas 
(N=21,237) 
* Date of the first refill was defined as 
the index date  
New Users of Sulfonylureas  
(N=14,081)  
Final Cohort: New Users of 
Sulfonylureas 
(N=11,730)  
Excluded patients aged <65 years or with 
prior mastectomy, prior cancer diagnosis, 
or prior renal disease diagnosis. 
Deleted observations
† 
Excluded 7,095 patients who were 
censored within 180 days after the index 
date due to developing cancer, death, or 
end of study (Induction Period) 
 
 
† One patient can contribute to multiple observations of new use, if applicable. Only the first 
observation for each patient was included in the final study cohort 
FIGURE 4.1. The flowchart of the study population 
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FIGURE 4.2. Cumulative Incidence of Breast Cancer by Treatment Cohort.  
The number of patients at risk at year 4 was not listed because our DUA prohibits us to present 
number less 11. 
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FIGURE 4.3. PS weighted hazard ratios (95% CI) over time comparing metformin 
initiators vs sulfonylureas initiators since follow-up, in as treated (top) and intention to 
treat (bottom) analyses.  
  
  
4
9
 
 
FIGURE 4.4. Propensity Score weighted hazard ratios (95% CIs) comparing metformin initiators vs sulfonylureas initiators, 
stratified by age group, race, and baseline use of statins, in as treated (top) and intention to treat (bottom) analyses.  
*Propensity score was re-estimated based on the same model for each subgroup.  
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CHAPTER 5. DIFFERENTIAL USE OF SCREENING MAMMOGRAPHY IN 
OLDER WOMEN INITIATING METFORMIN VERSUS SULFONYLUREAS 
I. Introduction 
Metformin is the most commonly prescribed drug for type 2 diabetes. It has been linked 
with possible beneficial effects on breast cancer incidence in several observational studies [1, 3, 
5, 32] but not in others [2, 4, 27-30]. Many of the studies reporting an inverse association 
between metformin and breast cancer risk may suffer from time-related biases as discussed in 
Suissa’s review article [7]. Another potential source of bias, detection bias due to differential 
healthcare utilization, could also affect the metformin-breast cancer association but has not been 
addressed so far. Differential detection of asymptomatic or pre-clinical cancer before treatment 
initiation could reduce cancer incidence after initiation by excluding women with early diagnosis.  
On the other hand, differential detection after initiation may lead to an increased incidence rate 
immediately following treatment initiation followed by a period of reduced incidence rate. 
Our previous study examined healthcare utilization comparing metformin and a clinical 
alternative, sulfonylureas, using data from Medicare claims [68]. We have noted that metformin 
initiators were more likely than sulfonylureas initiators to receive mammograms and to visit 
physicians around the time of initiation, potentially leading to biased detection of breast cancer. 
However, this study failed to distinguish screening from diagnostic mammography, thus the 
results did not reflect the actual difference in receipt of screening mammography between 
metformin and sulfonylureas initiators. Therefore, the objective of this study was to quantify the 
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risk of screening mammography and screen-detected breast cancer over 12-month periods pre- 
and post-initiation among metformin and sulfonylureas initiators.   
II. Methods 
Study Population 
This study used data from Medicare fee-for-service beneficiaries from January 1st, 2006 
to December 31st, 2012, including the denominator file, Part A (hospital claims), Part B 
(outpatient physician services), and Part D (dispensed prescription claims). Medicare offers free 
screening mammography every year for all women, minimizing the influences of socioeconomic 
disparity. Given that differential detection pre- and post-initiation would affect the effect 
estimates for incident breast cancer differently, this study had two study cohorts. One was the 
new user cohort which was used to examine use of screening mammography over a two-year 
window of 12 months pre- and post-initiation, primarily focusing on the period of 12 months 
prior to initiation. The other study cohort was the cancer-free cohort mimicking a cohort study on 
breast cancer incidence, which only examined use of screening mammography in 12 months 
after initiation.  
For the new user cohort, we identified women aged 65 or older who initiated 
monotherapy of metformin or sulfonylureas between 2008 and 2010. Initiation was defined as 
having at least one refill within 90 days after end of drug supply of the initial prescription and 
having at least 12 months of continuous Part D enrollment prior to initiation without use of any 
anti-diabetic drugs. Patients were classified as new users of metformin or sulfonylureas 
according to the initial prescription and the date of the first prescription was defined as the index 
date (i.e., initiation). Eligible patients were also required to have enrolled in Part A and B 
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continuously for ≥ 24 months pre-initiation and ≥ 12 months post-initiation, thus patients who 
died or disenrolled Medicare Part A and B within 12 months after initiation were excluded from 
the study.  
A study examining cancer incidence commonly requires a cancer-free study population. 
Thus, we had the cancer-free cohort to correctly assess receipt of screening mammography 
within 12 months following treatment initiation. This cancer-free cohort was a subgroup of the 
new user cohort, which included eligible initiators without a diagnosis of any cancer except for 
non-melanoma skin cancer within 12 months prior to initiation. The flowchart of the study 
cohort is available in Figure 5.1.   
Screening Mammography 
We used the following the Healthcare Common Procedure Coding System (HCPCS) 
codes to select all mammograms for the study cohort: G0202-G0205, 76091-76092, 77051-
77052, and 77056-77057. Mammograms were further classified as screening versus diagnostic 
test based on a claims-based algorithm [69]. Briefly, mammograms were considered as screening 
test if they were coded as screening mammography without a previous mammogram within prior 
9 months and without any breast cancer diagnosis in the prior year. This algorithm has been 
validated in Medicare claims with a high positive predictive value (PPV) of 94.9% [69]. The 
detail of this algorithm and the results were shown in Supplemental Figures 5.2-5.3.   
Screen-Detected Breast Cancer 
After distinguishing screening from diagnostic mammograms, we also used the Fenton 
algorithm to identify incident screen-detected breast cancers [70]. This algorithm has a high PPV 
of 88.0% among Medicare enrollees [70]. The Fenton algorithm classifies screening 
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mammograms as positive to detect breast cancer by requiring a breast cancer diagnosis within 
123 days post-mammogram and a breast-directed surgery within a year following the diagnosis, 
or by a diagnosis of carcinoma in-situ within 286 days post-mammogram with a subsequent 
mammogram within 82 days following the diagnosis. The detail of this algorithm and the results 
were shown in Figures 5.4-5.5.  To evaluate the performance of screening mammography in our 
cohorts, we calculated the screening detection rate for breast cancer by dividing the number of 
screen-detected breast cancers by the number of screening mammograms. The corresponding 
95% confidence intervals were estimated using the adjusted Wald method. 
Incident Breast Cancer 
In the cancer-free cohort, any incident breast cancer during 12-month follow-up was 
another outcome of interest, irrespective of whether it was detected by screening or due to 
symptoms. To be similar to the Fenton algorithm, we required a breast-directed surgery within a 
year following a breast cancer diagnosis code, including invasive and carcinoma in situ, to 
ascertain the breast cancer case.  
Statistical Analysis 
In the new user cohort, we began with a description of metformin and sulfonylureas 
initiators by receipt of screening mammography during a two-year window of 12 months pre- 
and post-initiation. The day of initiation was indexed as Month 0, and was included in the month 
following initiation (Month 1). Frequency of initiators receiving a screening mammogram was 
summarized within sequential 3-month and 12-month intervals from Month -12 (before initiation) 
to Month 12 (after initiation), respectively. Incident breast cancer detected at screening was 
calculated over 12-monthly intervals, given expected small numbers. We estimated risks and risk 
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differences (RDs) and their 95% confidence intervals (CIs) of each event during each time 
interval comparing metformin to sulfonylureas initiators.  To control the potential confounding, 
we used propensity score weighting method to standardize sulfonylureas initiators to metformin 
initiators on the following variables: age, race, calendar year of initiation, and number of 
physician visit in 12 months prior to initiation [47]. 
In the cancer-free study, we repeated all analyses during the time window of 12 months 
after initiation only and calculated RD of total breast cancer incidence comparing metformin to 
sulfonylureas groups in 12 months after initiation. Given the fact that screening mammography 
prior to initiation is likely associated with receiving subsequent screening tests after initiation, 
we additionally included the variable of prior screening in the propensity score model for 
confounding control. Furthermore, the analyses in this cancer-free cohort were stratified by 
receipt of screening mammography in 12 months prior to initiation. 
III. Results 
Our new user cohort included a total of 36,465 initiators of metformin and sulfonylureas 
during the study period.  Tables 5.1 and 5.2 summarize the baseline characteristics and the 
proportion of women who had a least 1 screening mammogram in 2 years between metformin 
and sulfonylureas initiators, respectively. Compared with sulfonylureas initiators, metformin 
initiators were younger, had less comorbidity such as cancer and cardiovascular disease, and had 
more physician visits. Patients were less likely to initiate sulfonylureas in more recent years, but 
were equally likely to initiate metformin over three years. Over a two-year window, 45% of the 
new user cohort received at least one screening mammogram. Approximately half of metformin 
initiators but only one-third of sulfonylureas initiators had at least one screening mammogram in 
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two years (Table 5.2). The proportion of women who had screening mammograms decreased 
largely with age but increased with number of physician visits in both groups.  Screening 
mammography was also less common in sicker patients, such as those with cardiovascular 
disease or hospital admission, but remained similar across calendar years.  
We present the proportion of patients receiving mammograms in 3-monthly intervals 
over 12 months before and after initiation in Figure 5.6. Metformin initiators were more likely to 
have screening mammograms than sulfonylureas initiators, which was evident and consistent 
over time. For both cohorts, the percentage of patients receiving screening mammograms was 
fairly stable over time; however, it clearly peaked in the 3 months immediately following 
initiation in metformin initiators but not in sulfonylureas initiators, resulting in a greater 
difference of 4 percentage points in this interval than other intervals (approximately 3 percentage 
points). 
We identified a total of 16,788 and 4,537 screening mammograms over two years in 
13,220 (50%) metformin initiators and 3,312 (33%) sulfonylureas initiators, respectively (Table 
5.3). The weighted RD of screening mammography comparing metformin to sulfonylureas 
groups was 10 percentage points (95% CI: 9 to 10). We also examined use of screening 
mammograms before and after initiation, separately (Table 5.4).  During 12 months prior to 
initiation, we found 9,210 (35%) and 2,274 (23%) initiators of metformin and sulfonylureas who 
had at least one screening mammogram, respectively, resulting in a weighted RD of 7 percentage 
points (95% CI: 6 to 8).  Similar results were found for the analyses during 12 months after 
initiation (weighted RD: 8 percentage points; 95% CI: 7 to 9).   
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We found 137 and 23 incident breast cancer was detected at screening mammograms 
among metformin and sulfonylureas groups, respectively (Table 5.3). The risk of incident breast 
cancer detected at screen was 0.52% in metformin, as compared with 0.23% in sulfonylureas, 
with a weighted RD of 0.17 percentage points (95% CI: 0.06 to 0.28). However, a higher 
absolute risk of screen-detected breast cancer was observed for metformin group during 12 
months after initiation (weighted RD: 0.12 percentage points; 95% CI: 0.04 to 0.21), but not 
during 12 months before initiation (weighted RD: 0.05 percentage points; 95% CI: -0.02 to 0.12) 
(Table 5.4). 
We found similar patient characteristics (Tables 5.5-5.6) and the results of screening 
mammography and screen-detected breast cancer during 12 months after initiation in the cancer-
free study cohort (Tables 5.7). Consistently, metformin initiators were more likely to receive 
screening mammograms than sulfonylureas initiators (weighted RD: 6 percentage points; 95% 
CI: 5 to 7). The risk of screen-detected breast cancer was higher in metformin (0.33%) than 
sulfonylureas (0.13%), but differences became attenuated after accounting for imbalances in 
baseline characteristics (weighted RD: 0.09 percentage points; 95% CI: -0.01 to 0.19). Although 
metformin was not associated with the risk of total breast cancer within 1 year after initiation 
(weighted RD: 0.06 percentage points; 95% CI: -0.07 to 0.19), more breast cancer cases were 
actually detected by screening in metformin initiators (62%) than sulfonylureas initiators (34%).  
We stratified the analyses by receipt of screening mammography in 12 months prior to 
initiation (Table 5.8). Women screened in previous 12 months were more likely to receive 
screening mammograms in the following 12 months after initiation than those not screened, 
consistently in both metformin and sulfonylureas groups. The risk difference in screening 
mammograms between metformin and sulfonylureas was larger for women not screened 
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previously than those screened. In addition, the positive association between metformin and 
higher risks of screen-detected breast cancer and total breast cancer was only found among 
women not previously screened, but not among women previously screened (Table 5.9).  As 
expected, the screening detection rate for incident breast cancer was higher among women not 
previously screened. 
IV. Discussion and Conclusions 
In this study, we found that older women initiating metformin were not only more 
frequently screened for breast cancer in 12 months before initiation than women initiating 
sulfonylureas, but they also had more subsequent screening mammograms in the 12 months after 
initiation, especially those women not screened in the year pre-initiation. Consequently, 
compared with sulfonylureas initiators, metformin initiators had higher probabilities of screen-
detected breast cancer both in the 12 months before and after initiation. These results indicate 
existence of detection bias due to differential screening mammography pre- and post-initiation 
when comparing breast cancer incidence between women initiating metformin and women 
initiating sulfonylureas.  
A total of 45% of all eligible initiators in our study underwent at least one screening 
mammogram over two-year time window, far less than that reported by US Centers for Disease 
Control and Prevention, which estimated 65.5% of women aged 65 years and over in 2008 
having a mammogram within the past 2 years [71]. Nevertheless, our results were similar to the 
previous study of 5% Medicare random sample, which reported that 40.2% of women aged 65+ 
years in Medicare during 2005-2006 had at least one screening mammography [72]. We also 
observed that receipt of screening mammography was associated inversely with age but 
 58 
positively with number of physician visits. Although the United States Preventive Services Task 
Force (USPSTF) recommendations on screening mammography changed in 2009, no difference 
was observed on use of screening mammography across calendar years. These findings are 
consistent with previous studies [72, 73].  The overall detection rate for screen-detected breast 
cancer was 6.9 per 1,000 screening examinations in our study, similar to Breast Cancer 
Surveillance Consortium 2009 data which ranges from 6.1 to 8.5 as age increases from 65 to 
85+ . 
It is unknown why the use of screening mammography could differ between metformin 
and sulfonylureas initiators since both groups represented similar diabetic patients newly 
prescribed with oral anti-diabetic drugs, but we speculate that it could be related to prescriber’s 
behavior. The USPSTF recommends biennial screening mammography for women aged 50-74 
years . Previous studies also have shown that physician recommendation is one strong motivation 
for undergoing screening mammography [75, 76]. Given that metformin is recommended as the 
preferred initial treatment for diabetes except for patients with chronic kidney disease, metformin 
prescribers who comply with guideline recommendations may be more likely to perform regular 
examinations or to recommend cancer screening tests for older patients. Thus, women initiating 
metformin may be more likely to receive screening mammography and, consequently, to be 
diagnosed with breast cancer around the time of initiation. While this theory is purely speculative, 
we observed a sudden increase in the probability of receiving screening mammography in the 3 
months after initiation in metformin group but not in sulfonylureas group, indicating a possible 
role of the prescribers on promoting screening mammography. This finding may provide some 
support for our speculation. 
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Differential detection of breast cancer due to differential screening mammography before 
and after drug initiation has distinct influences on effect estimates, thus our results need to be 
interpreted separately. Differential screening mammography before initiation which we observed 
in the new user cohort suggests that metformin initiators may be at slightly lower risk of breast 
cancer than sulfonylureas initiators at the time of initiation because more asymptomatic breast 
cancer cases were excluded from metformin group, in spite of the fact that the difference in the 
probability of screen-detected breast cancer was small.  
On the other hand, differential screening mammography after initiation would increase 
the breast cancer incidence in metformin initiators immediately following treatment initiation 
and would decrease the breast cancer incidence thereafter because of the “premature” detection 
of preclinical breast cancer that would eventually become clinical and be diagnosed without 
screenings. One cohort study examined metformin users in UK clinical practice research datalink 
(CPRD) and found the pattern of a higher breast cancer risk in the first 6 months since initiation 
than later [32], supporting our hypothesis. This may also explain the unexpected increased 
incidence of breast cancer in metformin users which was observed in one cohort study of US 
Medicare claims [28], and, in addition to time-related bias [7], might also partially explain the 
benefits of metformin on breast cancer incidence which was only observed after long-term 
treatment in one CPRD case-control study [1].  
Interestingly enough, in cohort studies of cancer incidence in which follow-up begins 
only 6 or 12 months after drug initiation to account for a likely induction period for cancer 
development, differential screening after initiation could lead to a relative lower risk of breast 
cancer for metformin initiators given more cases of screen-detected breast cancer are excluded 
from metformin initiators than sulfonylureas initiators. Together, our results on differential 
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screening mammography are unlikely to explain why we should observe no association between 
metformin in comparison with sulfonylureas and breast cancer as observed in some studies 
assuming a real protective effect of metformin [27, 29, 30]. Our results might, however, at least 
partially explain a reduced risk of breast cancer associated with metformin as observed in one 
cohort study with sulfonylureas as a comparison group [5] and in several studies with different 
comparison groups [1-3] assuming no effect of metformin on breast cancer incidence.   
This study has some limitation. First, our study is limited by the small number of screen-
detected breast cancer cases, thus the effect estimates (i.e., RD) were imprecise. We 
acknowledge that we did not have a large enough study population to detect a small difference in 
the risk of screen-detected breast cancer during the study period. Secondly, we may have 
underestimated true cases of breast cancer detected at screening. To ascertain breast cancer cases, 
we required a breast surgery following a breast cancer diagnosis, according to the Fenton 
algorithm [69]. Although surgery is the primary and most effective treatment for breast cancer, it 
is still possible that older and sicker women may not have surgery [77]. Given the limitations due 
to sample size, we did not use information on prescriber’s characteristics to evaluate our 
speculation that differential screening test may be related to prescriber’s behavior. Lastly, 
Medicare part B plan provides free annual screening mammography for women aged 65 years or 
older, reducing health inequalities for receiving mammography. Thus, our results can be 
generalized to US older women, but may not be generalized to younger women or women 
residing in other countries in which do not provide full coverage of screening mammography for 
older women and socioeconomic status likely affects the probability of receiving screening 
mammography. Generalizability of the study results may be limited within Medicare population.  
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Our study provides empirical evidence for biased detection for breast cancer due to more 
screening mammograms performed in older women initiating metformin compared with 
sulfonylureas around the time of initiation. Researchers should be aware of the potential for more 
screening mammograms pre- and post-initiation when interpreting the findings of studies 
assessing the effects of metformin on breast cancer incidence. 
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V. Tables and Figures 
TABLE 5.1. Characteristics at baseline among metformin and sulfonylureas initiators in 
the new user cohort 
Characteristics 
Metformin 
 
Sulfonylureas 
             N (%) 
 
             N (%) 
Total N 26532  (100.0) 
 
9933  (100.0) 
Age, years      
Median 73.0 
 
77.0 
Interquartile Range (IQR) (69.0-79.0) (71.0-84.0) 
Category 
  
 
 
 65 - 69 7362  (27.7) 
 
2039 (20.5) 
70-74 7656  (28.9) 
 
1874  (18.9) 
75-79 5299  (20.0) 
 
1871  (18.8) 
80-84 3615  (13.6) 
 
1874  (18.9) 
85+ 2600  (9.8) 
 
2275  (22.9) 
Race  
  
 
 
        White 21488  (81.0) 
 
7788 (78.4) 
       Black 2685  (10.1) 
 
1347  (13.6) 
       Others 2359  (8.9) 
 
798  (8.0) 
Comorbidity   
 
 
 Breast Cancer 1491  (5.6) 
 
538 (5.4) 
Any Cancer 3559  (13.4) 
 
1526  (15.4) 
Congestive Heart Failure 3571  (13.5) 
 
2645  (26.6) 
Ischemic Heart Disease 6715  (25.3) 
 
3497  (35.2) 
Hypertension 22456  (84.6) 
 
8521  (85.8) 
HealthCare Utilization   
 
 
 Days of Hospitalization 
  
 
 
 0 21124  (79.6) 
 
6531 (65.8) 
1 to 7 3614  (13.6) 
 
1925  (19.4) 
8+ 1794 (6.8) 
 
1477 (14.9) 
N of Physician Office Visit 
  
 
 
 ≤ 3 3734 (14.1) 
 
1782 (17.9) 
4 to 6 3205  (12.1) 
 
1083  (10.9) 
7 to 12 6618  (24.9) 
 
2245  (22.6) 
13+ 12975  (48.9) 
 
4823  (48.6) 
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TABLE 5.1. (Continued) Characteristics at baseline among metformin and sulfonylureas 
initiators in the new user cohort 
Characteristics 
Metformin  Sulfonylureas 
             N (%)               N (%) 
Location 
  
 
 
        Mid West 6644  (25.0) 
 
2571 (25.9) 
       North East 4287  (16.2) 
 
1898  (19.1) 
       South 10552  (39.8) 
 
4113  (41.4) 
       West 4882  (18.4) 
 
1279  (12.9) 
       Others 167  (0.6) 
 
72  (0.7) 
Prescriber Specialty 
  
 
 
        Internal Medicine - Diabetes 586  (2.2) 
 
180 (1.8) 
       Internal Medicine - Family Medicine 10213  (38.5) 
 
3428  (34.5) 
       Internal Medicine - General Practice 411  (1.5) 
 
164  (1.7) 
       Internal Medicine - Others 9404  (35.4) 
 
4138  (41.7) 
       Physician - Others 1225  (4.6) 
 
468  (4.7) 
       Physician Assistance 1964  (7.4) 
 
550  (5.5) 
       Others 2729  (10.3) 
 
1005  (10.1) 
Calendar Year of Initiation 
  
 
 
        2008 8749  (33.0) 
 
3665 (36.9) 
       2009 8935  (33.7) 
 
3389  (34.1) 
       2010 8848  (33.3) 
 
2879  (29.0) 
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TABLE 5.2. Proportions of women receiving at least one screening test within 2-year 
window of 12 months before and after initiation. 
Characteristics 
Metformin 
 
Sulfonylureas 
 
Screening 
Difference (%) % screened 
 
% screened 
 Total N 49.8 
 
33.3 
 
16.5 
Age, years      
Median 72.0  
 
75.0  
  Interquartile Range (IQR) (69.0-77.0) (70.0-80.0) 
Category 
 
 
 
  65 - 69 53.9 
 
37.5 
 
16.4 
70-74 57.5 
 
45.4 
 
12.1 
75-79 52.2 
 
39.6 
 
12.6 
80-84 41.6 
 
31.5 
 
10.1 
85+ 22.3 
 
16.1 
 
6.3 
Race  
 
 
 
         White 50.8 
 
34.3 
 
16.6 
       Black 48.2 
 
33.2 
 
15.0 
       Others 42.8 
 
24.7 
 
18.1 
Comorbidity  
 
 
  Breast Cancer 9.8 
 
7.4 
 
2.4 
Any Cancer 35.4 
 
27.0 
 
8.4 
Congestive Heart Failure 35.1 
 
24.3 
 
10.7 
Ischemic Heart Disease 45.2 
 
31.3 
 
14.0 
Hypertension 50.5 
 
34.0 
 
16.5 
HealthCare Utilization  
 
 
  Days of Hospitalization 
 
 
 
  0 52.5 
 
36.8 
 
15.7 
1 to 7 43.3 
 
29.0 
 
14.3 
8+ 31.5 
 
23.7 
 
7.8 
N of Physician Office Visit 
 
 
 
  ≤ 3 29.2 
 
16.8 
 
12.4 
4 to 6 39.8 
 
24.3 
 
15.5 
7 to 12 51.9 
 
32.7 
 
19.2 
13+ 57.2 
 
41.8 
 
15.4 
 
  
 65 
 
TABLE 5.2. (Continued) Proportions of women receiving at least one screening test within 
2-year window of 12 months before and after initiation. 
Characteristics 
Metformin 
 
Sulfonylureas 
 
Screening 
Difference (%) % screened 
 
% screened 
 Total N 49.8 
 
33.3 
 
16.5 
Location 
 
 
 
         Mid West 52.2 
 
34.8 
 
17.4 
       North East 48.9 
 
31.4 
 
17.5 
       South 49.3 
 
33.8 
 
15.4 
       West 48.9 
 
32.5 
 
16.3 
       Others 40.1 
 
19.4 
 
20.7 
Prescriber Specialty 
 
 
 
         Internal Medicine - Diabetes 59.4 
 
41.1 
 
18.3 
       Internal Medicine - Family 
Medicine 
48.2 
 
31.7 
 
16.5 
       Internal Medicine - General 
Practice 
38.9 
 
23.8 
 
15.1 
       Internal Medicine - Others 52.3 
 
34.9 
 
17.4 
       Physician - Others 44.7 
 
30.8 
 
14.0 
       Physician Assistance 51.8 
 
38.2 
 
13.7 
       Others 47.9 
 
31.2 
 
16.6 
Calendar Year of Initiation 
 
 
 
         2008 50.0 
 
33.0 
 
17.0 
       2009 50.0 
 
34.4 
 
15.7 
       2010 49.4 
 
32.6 
 
16.8 
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TABLE 5.3. Frequency of screening mammograms and screen-detected breast 
cancer over 2 years in the new user cohort, by treatment group 
Clinical Event 
  Mammograms 
over 24 months 
 
Cohort   MET SUL 
Total Patients, n 
 
26,532 9,933 
Screening Mammography 
   
N of screening mammograms 
 
18,788 4,537 
N of patients receiving ≥ 1 screening 
mammogram, n (%) 
13,220 (49.8) 3,312 (33.3) 
Crude RD,% (95% CI)* 
 
16.5 (15.4 to 17.6) 
Weighted RD,% (95% CI)*
,†
   9.5 (8.7 to 10.3) 
Breast Cancer detected at Screening 
Screen-detected BC case, n (%) 
 
137 (0.52) 23 (0.23) 
Crude RD,% (95% CI)* 
 
0.28 (0.16 to 0.41) 
Weighted RD,% (95% CI)*
 , †
 
 
0.17 (0.06 to 0.28) 
Screening detection rate for breast 
cancer per 1,000 tests
§
 
  
7.3  
(6.2 to 8.6) 
5.3  
(3.3 to 7.6) 
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylureas; RD: risk difference. 
* RD was estimated comparing metformin initiators to sulfonylureas initiators.  
† Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for 
metformin initiators and the odds of the estimated propensity score for sulfonylureas initiators. 
Propensity score model includes age, race, calendar year of initiation, and number of physician visit in 12 
months prior to initiation. 
§ Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer 
divided by total number of screening mammograms.  
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TABLE 5.4. Frequency of screening mammograms and screen-detected breast cancer over 2 years in 
the new user cohort, stratified by time interval before and after initiation 
Clinical Event 
  Screening mammograms before and after initiation 
 
12 months before initiation 
 
12 months after initiation 
Cohort   MET SUL 
 
MET SUL 
Total Patients, n 
 
26,532 9,933  26,532 9,933 
Screening Mammography 
      
N of screening mammograms 
 
9,224 2,276 
 
9,564 2,261 
N of patients receiving ≥ 1 screening 
mammogram, n (%) 
9,210 (34.7) 2,274 (22.9) 
 
9,543 (36.0) 2,260 (22.8) 
Crude RD,% (95% CI)* 
 
11.8 (10.8 to 12.8)  13.2 (12.2 to 14.2) 
Weighted RD,% (95% CI)*
,†
   7.1 (6.3 to 7.8)  7.8 (7.0 to 8.6) 
Breast Cancer detected at Screening 
Screen-detected BC case, n (%) 
 
53 (0.20) 12 (0.12) 
 
84 (0.32) 11 (0.11) 
Crude RD,% (95% CI)* 
 
0.08 (-0.01 to 0.17)  0.21 (0.11 to 0.30) 
Weighted RD,% (95% CI)*
 , †
 
 
0.05 (-0.02 to 0.12)  0.12 (0.04 to 0.21) 
Screening detection rate for breast cancer 
per 1,000 tests
§
 
  
5.9  
(4.4 to 7.5) 
5.7  
(2.9 to 9.3)  
8.9  
(7.1 to 10.9) 
5.3  
(2.6 to 8.8) 
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylureas; RD: risk difference. 
* RD was estimated comparing metformin initiators to sulfonylureas initiators.  
† Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin initiators and the odds 
of the estimated propensity score for sulfonylureas initiators. Propensity score model includes age, race, calendar year of 
initiation, and number of physician visit in 12 months prior to initiation. 
§ Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer divided by total number 
of screening mammograms.  
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TABLE 5.5. Characteristics at baseline among metformin and sulfonylureas initiators in 
the cancer-free cohort. 
Characteristics 
Metformin 
 
Sulfonylureas 
N (%) 
 
N (%) 
Total N 22973  (100.0)  8407  (100.0) 
Age, years      
Median 73  77 
Interquartile Range (IQR) (69-79)  (70-84) 
Category      
65-69 6549  (28.5)  1821  (21.7) 
70-74 6591  (28.7)  1548  (18.4) 
75-79 4524  (19.7)  1578  (18.8) 
80-84 3086  (13.4)  1554  (18.5) 
85+ 2223  (9.7)  1906  (22.7) 
Race       
       White 18455  (80.3)  6495  (77.3) 
       Black 2368  (10.3)  1188  (14.1) 
       Others 2150  (9.4)  724  (8.6) 
Comorbidity      
Congestive Heart Failure 3028  (13.2)  2192  (26.1) 
Ischemic Heart Disease 5691  (24.8)  2881  (34.3) 
Hypertension 19297  (84.0)  7135  (84.9) 
HealthCare Utilization      
Days of Hospitalization      
0 18633  (81.1)  5739  (68.3) 
1 to 7 2914  (12.7)  1539  (18.3) 
8+ 1426 (6.2)  1129 (13.4) 
N of Physician Office Visit      
≤ 3 3607 (15.7)  1709 (20.3) 
4 to 6 3006  (13.1)  1002  (11.9) 
7 to 12 5916  (25.8)  1963  (23.3) 
13+ 10444  (45.5)  3733  (44.4) 
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TABLE 5.5. (Continued) Characteristics at baseline among metformin and sulfonylureas 
initiators in the cancer-free cohort. 
Characteristics 
Metformin 
 
Sulfonylureas 
N (%) 
 
N (%) 
Location      
       Mid West 5744  (25.0)  2158  (25.7) 
       North East 3619  (15.8)  1565  (18.6) 
       South 9200  (40.0)  3519  (41.9) 
       West 4269  (18.6)  1104  (13.1) 
       Others 141  (0.6)  61  (0.7) 
Prescriber Specialty      
       Internal Medicine - Diabetes 467  (2.0)  147  (1.7) 
       Internal Medicine - Family Medicine 8906  (38.8)  2955  (35.1) 
       Internal Medicine - General Practice 371  (1.6)  149  (1.8) 
       Internal Medicine - Others 8070  (35.1)  3425  (40.7) 
       Physician - Others 1055  (4.6)  392  (4.7) 
       Physician Assistance 1749  (7.6)  475  (5.7) 
       Others 2355  (10.3)  864  (10.3) 
Calendar Year of Initiation      
       2008 7604  (33.1)  3135  (37.3) 
       2009 7706  (33.5)  2881  (34.3) 
       2010 7663  (33.4)  2391  (28.4) 
Prior Screening Mammograms 8374  (36.5)  1983  (23.6) 
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TABLE 5.6. Proportions of women receiving at least one screening test within 2-year 
window of 12 months before and after initiation. 
Characteristics 
Metformin 
 
Sulfonylureas 
 
Screening 
Difference (%) % screened 
 
% screened 
 Total N 37.9  23.8 14.1 
Age, years      
Median 72  74  
-- Interquartile Range (IQR) (69-76)  (69-79)  
Category      
65-69 43.2  28.8  14.4 
70-74 44.1  35.5  8.6 
75-79 38.9  27.1  11.8 
80-84 29.7  21.3  8.4 
85+ 13.1  8.7  4.4 
Race       
       White 38.9  24.4  14.5 
       Black 37.7  24.3  13.4 
       Others 29.5  17.4  12.1 
Comorbidity      
Congestive Heart Failure 24.2  15.6  8.7 
Ischemic Heart Disease 32.8  21.4  11.3 
Hypertension 37.8  23.7  14.1 
HealthCare Utilization      
Days of Hospitalization      
0 40.1  26.9  13.2 
1 to 7 32.0  18.7  13.3 
8+ 20.9  15.0  5.9 
N of Physician Office Visit      
≤ 3 27.0  15.9  11.1 
4 to 6 29.0  16.8  12.3 
7 to 12 38.6  21.4  17.2 
13+ 43.7  30.5  13.3 
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TABLE 5.6. (Continued) Proportions of women receiving at least one screening test within 
2-year window of 12 months before and after initiation. 
Characteristics 
Metformin 
 
Sulfonylureas 
 
Screening 
Difference (%) % screened 
 
% screened 
 Location     
       Mid West 40.5  25.6  15.0 
       North East 38.0  22.2  15.8 
       South 37.1  24.2  12.9 
       West 36.2  21.7  14.4 
       Others 27.7  11.5  16.2 
Prescriber Specialty      
       Internal Medicine - Diabetes 44.1  30.6  13.5 
       Internal Medicine - Family Medicine 35.8  23.7  12.1 
       Internal Medicine - General Practice 29.1  16.8  12.3 
       Internal Medicine - Others 40.9  23.9  16.9 
       Physician - Others 33.3  22.2  11.1 
       Physician Assistance 40.0  28.2  11.8 
       Others 36.1  21.8  14.3 
Calendar Year of Initiation      
       2008 38.3  23.2  15.1 
       2009 38.1  24.5  13.6 
       2010 37.3  23.6  13.6 
Prior Screening Mammograms 61.1  54.5  6.6 
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TABLE 5.7. Frequency of screening mammograms, screen-detected breast cancer, and 
total breast cancer over 12 months after initiation in the cancer-free cohort, by treatment 
group. 
Clinical Event 
  
Mammograms in 12 months after initiation 
 
Cohort   MET SUL 
Total Patients, n 
 
22,973 8,407 
Screening Mammography  
 
  
N of screening mammograms 
 
8,721 1,999 
N of patients receiving ≥ 1 screening 
mammogram, n (%) 
8,701(37.9) 1,998 (23.8) 
Crude RD,% (95% CI)* 
 
14.1 (13.0 to 15.2) 
Weighted RD,% (95% CI)*
, †
   6.0 (5.2 to 6.9) 
Breast Cancer detected at Screening 
Screen-detected BC case, n (%) 
 
75 (0.33) 11 (0.13) 
Crude RD,% (95% CI)* 
 
0.20 (0.09 to 0.30) 
Weighted RD,% (95% CI)*
 , †
 
 
0.09 (-0.01 to 0.19) 
Screening detection rate for breast 
cancer per 1,000 tests
§
 
  
8.7  
(6.9 to 10.8) 
6.0 
(2.9 to 10.0) 
Incident Breast Cancer 
BC cases (%) 
 
121 (0.53) 31 (0.37) 
Crude RD,% (95% CI)* 
 
0.16 (-0.00 to 0.32) 
Weighted RD,% (95% CI)* 
 
0.06 (-0.07 to 0.19) 
% of BC detected by screening
‡
  62.0 35.5 
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylureas; RD: risk difference; N/S: 
not specified. 
* RD was estimated comparing metformin initiators to sulfonylureas initiators.  
† Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin 
initiators and the odds of the estimated propensity score for sulfonylureas initiators. Propensity score model 
includes age, race, prior use of screening mammography, calendar year of initiation, and number of physician 
visit in 12 months prior to initiation.  
§ Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer divided 
by total number of screening mammograms.  
‡ Percent of breast cancer detected by screening was calculated by cases of screen-detected breast cancer divided 
by total cases of breast cancers 
¶ Our DUA does not allow us to present cell sizes <11, so the number for these cells were not presented on this 
table. 
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TABLE 5.8. Frequency of screening mammograms and screen-detected breast cancer over 12 months after initiation in the 
cancer-free cohort, stratified by receipt of screening mammography within 12 months prior to initiation. 
Clinical Event 
  
Receipt of screening mammography within 12 months prior to 
initiation 
 
Yes  No 
Cohort   MET SUL 
 
MET SUL 
Total Patients, n 
 
8,374 1,983  14,599 6,424 
Screening Mammography  
 
     
N of screening mammograms 
 
5,124 1,081  3,597 918 
N of patients receiving ≥ 1 screening mammogram, n 
(%) 
5,114 (61.1) 1,081 (54.5)  3,587 (24.6) 917 (14.3) 
Crude RD,% (95% CI)* 
 
6.6 (4.1 to 9.0)  10.3 (9.2 to 11.4) 
Weighted RD,% (95% CI)*
, †
   4.4 (2.8 to 5.9)  6.2 (5.2 to 7.1) 
Breast Cancer detected at Screening 
Screen-detected BC case, n (%) 
 
29 (0.35) <11 (<0.55)
¶
  46 (0.32) <11 (<0.17)
 ¶
 
Crude RD,% (95% CI)* 
 
N/S
¶
  N/S
¶
 
Weighted RD,% (95% CI)*
 , †
 
 
-0.06 (-0.26 to 0.14)  0.16 (0.05 to 0.27) 
Screening detection rate for breast cancer per 1,000 
tests
§
 
  
5.7  
(3.8 to 8.1) 
<10.2
¶
  
12.8 
(9.4 to 17.0) 
<12.0
¶
 
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylureas; RD: risk difference; N/S: not specified. 
* RD was estimated comparing metformin initiators to sulfonylureas initiators.  
† Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin initiators and the odds of the estimated 
propensity score for sulfonylureas initiators. Propensity score model includes age, race, prior use of screening mammography, calendar year of initiation, and 
number of physician visit in 12 months prior to initiation.  
§ Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer divided by total number of screening mammograms.  
‡ Percent of breast cancer detected by screening was calculated by cases of screen-detected breast cancer divided by total cases of breast cancers 
¶ Our DUA does not allow us to present cell sizes <11, so the number for these cells were not presented on this table. 
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TABLE 5.9. Frequency of total breast cancer over 12 months after initiation in the cancer-free cohort, 
stratified by receipt of screening mammography within 12 months prior to initiation. 
Clinical Event 
  
Receipt of screening mammography within 12 months prior 
to initiation 
 
Yes  No 
Cohort   MET SUL 
 
MET SUL 
Incident Breast Cancer 
BC cases (%) 
 
33 (0.39) <11 (<0.55)
 ¶
  88 (0.60) 21 (0.33) 
Crude RD,% (95% CI)* 
 
N/S
¶
  N/S
¶
 
Weighted RD,% (95% CI)* 
 
-0.24 (-0.47 to -0.00)  0.21 (0.05 to 0.37) 
% of BC detected by screening
‡
  87.9 N/S
¶
  52.3 N/S
¶
 
Abbreviations: BC: breast cancer; N: number; MET: metformin; SUL: sulfonylureas; RD: risk difference; N/S: not specified. 
* RD was estimated comparing metformin initiators to sulfonylureas initiators.  
† Weighted by standardizing to their distribution in metformin initiators by using weights of 1 for metformin initiators and the odds 
of the estimated propensity score for sulfonylureas initiators. Propensity score model includes age, race, prior use of screening 
mammography, calendar year of initiation, and number of physician visit in 12 months prior to initiation. For analyses stratified 
by receipt of prior screening mammography, propensity score was re-estimated based on the model including age, race, prior use 
of screening mammography, calendar year of initiation, and number of physician visit.  
§ Screening detection rate for breast cancer was calculated by total cases of screen-detected breast cancer divided by total number 
of screening mammograms.  
‡ Percent of breast cancer detected by screening was calculated by cases of screen-detected breast cancer divided by total cases of 
breast cancers 
¶ Our DUA does not allow us to present cell sizes <11, so the number for these cells were not presented on this table. 
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FIGURE 5.1. The flowchart of study cohort.  
Abbreviations: MET: metformin; SUL: sulfonylureas. 
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FIGURE 5.2. Allocation of mammograms by screening versus diagnostic purpose in the new user cohort.  
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FIGURE 5.3. Allocation of mammograms by screening versus diagnostic purpose in the cancer-free cohort.     
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FIGURE 5.4.  Algorithm for identifying incident breast cancer detected at screening mammography in the new user cohort.  
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FIGURE 5.5.  Algorithm for identifying incident breast cancer detected at screening mammography in the cancer-free cohort. 
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FIGURE 5.6.  Proportions of women receiving a screening mammogram over time by 
treatment group, in the new user cohort. 
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FIGURE 5.7. Proportions of women receiving a screening mammogram over time by 
treatment group in the cancer-free cohort. 
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CHAPTER 6. CONCLUSIONS 
I. Summary of Findings 
This study used data from 2007-2011 Medicare claims to conduct the large, population-
based study using a state-of-the art new user, active comparator cohort design to investigate the 
association between metformin and the risk of breast cancer. We found that older women 
initiating metformin did not have a lower risk for breast cancer than women initiating a 
therapeutic alternative, sulfonylureas. The results of no effects were consistent in both as-treated 
(AT) and intention-to-treat (ITT) analyses. The analyses stratified by duration of treatment after 
initiation showed no decreasing trend associated with metformin over time. No reduced risk of 
breast cancer associated with metformin was also found when comparing metformin initiators to 
initiator of Thiazolidinediones (TZD)/incretin or to diabetic initiators of angiotensin-converting-
enzyme (ACE) inhibitor, and were consistent across a variety of sensitivity analyses. There was 
no indication of a protective effect across the age groups and in either subgroup defined by prior 
statin use. However, we did observe a possible tendency towards a lower risk of breast cancer 
associated with metformin in African American women, despite the wide corresponding 
confidence interval due to the small number of events.   
The external validation study of Medicare Current Beneficiary Survey (MCBS) showed 
that being obese (BMI: ≥30) and ever smokers were not associated with metformin initiation, 
after multivariable adjustment, indicating little difference in BMI and smoking status conditional 
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on controlling for other differences. Using the information from MCBS, we used propensity 
score calibration (PSC) to control for unmeasured confounding by BMI and smoking in the 
analyses of Medicare data. We consistently observed no metformin-breast cancer associations 
after implementing PSC. 
Receipt of screening mammography may differ between metformin and sulfonylureas 
initiators. This study showed that older women initiating metformin were not only more 
frequently screened for breast cancer in 12 months before initiation than women initiating 
sulfonylureas, but they also had more subsequent screening mammograms in the 12 months after 
initiation, especially those women not screened in the year pre-initiation. Consequently, 
compared with sulfonylureas initiators, metformin initiators had higher probabilities of screen-
detected breast cancer both in the 12 months before and after initiation. These results indicate 
existence of detection bias due to differential screening mammography pre- and post-initiation 
when comparing breast cancer incidence between women initiating metformin and women 
initiating sulfonylureas.  
In conclusion, our findings suggest that metformin does not reduce the risk for breast 
cancer among women aged 65 years or older, supporting the notion that the reduced risk of 
breast cancer associated with metformin observed in the previous studies is likely due to time-
related biases. There was little residual confounding by unmeasured BMI and smoking status, 
after controlling imbalance of measured variables between metformin and sulfonylureas 
initiators. Despite an observation of possible detection bias due to differential screening 
mammography, it is unlikely explains no metformin-breast cancer association observed in this 
study, assuming a real protective effect of metformin. Overall, this study provides no support for 
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a reduced risk of breast cancer after initiation of metformin compared with a clinical alternative, 
sulfonylureas, in older women.  
II. Strengths 
This study builds on previous studies but adds to the science by reducing the potential for 
various biases for various reasons. First, we employed the active comparator new user design and 
define cohort entry and the start of follow-up carefully to avoid immortal time bias. We used the 
active comparator of sulfonylureas initiators in the analyses for Aim 1a (Breast Cancer Risk) and 
another two active comparators of TZDs/Incretins and ACE inhibitors in the sensitivity analyses. 
Use of active comparator group can increase comparability between cohorts and minimize the 
healthy user effect. Secondly, in follow-up approaches, we have given considerations on 
induction period (cancer development) and latency periods (carry-over effect and clinical 
detection for breast cancer). Cancer usually takes many years to develop and has a long latency 
period between a relevant exposure and the clinical detection. A disregard for the effect of 
latency periods might lead to a biased estimate of the association of interest. Furthermore, our 
study examined the potential effects of unmeasured confounders and detection bias, which has 
not been examined in previous metformin-breast cancer studies. The findings do no only 
strengthen our results from Aim 1a (Breast Cancer Risk) but also benefit future metformin-
cancer studies. 
III. Limitations 
The study conducted to address Aim 1 (Breast Cancer and Unmeasured Variables) is 
limited by the short follow-up time (up to 4.5 years), and we should be aware of this limitation 
when interpreting the results.  Nevertheless, diabetes treatment regimens are usually modified 
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over time for adequate glycemic control as diabetes progresses, so the observed relative short 
duration reflects actual treatment dynamics in the real world setting (median: 0.79 year; 
Interquartile Range: 0.35 to 1.65) in the AT analysis. In the ITT analysis which ignored 
treatment changes during follow-up, the follow-up time was almost double (median: 1.53 years; 
IQR: 0.69 to 2.56), but still short for evaluating a cancer outcome. We thus cannot exclude the 
possibility of a beneficial effect of long-term use of metformin on breast cancer risk. In addition, 
confounding by unmeasured variables may still exist, although we examined the impact of two 
major unmeasured confounders, BMI and smoking, however, suggesting little residual 
confounding. The Medicare and MCBS fail to capture information on some risk factors for 
breast cancer, such as family history of breast cancer, age at menopause and giving first birth, 
and drinking alcohol. We were not able to control for these variables. However, these factors are 
not likely to affect the choice between metformin and sulfonylureas initiation. For outcome 
ascertainment, we did not independently validate the diagnoses of breast cancer, but our 
algorithm based on ICD-9 codes has been validated with cancer registry data in an, albeit 
selected, Medicare population [44] and have been used extensively in pharmacoepidemiological 
studies. 
For Aim 2 (Screening Mammography), the study is limited by the small number of 
screen-detected breast cancer cases, thus the effect estimates (i.e., risk difference) were imprecise. 
We acknowledge that we did not have a large enough study population to detect a small 
difference in the risk of screen-detected breast cancer during the study period. Secondly, we may 
have underestimated true cases of breast cancer detected at screening. To ascertain breast cancer 
cases, we required a breast surgery following a breast cancer diagnosis, according to the Fenton 
algorithm [69]. Although surgery is the primary and most effective treatment for breast cancer, it 
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is still possible that older and sicker women may not have surgery [77]. Given the limitations due 
to sample size, we did not use information on prescriber’s characteristics to evaluate our 
speculation that differential screening test may be related to prescriber’s behavior. Lastly, 
Medicare part B plan provides free annual screening mammography for women aged 65 years or 
older, reducing health inequalities for receiving mammography. Thus, our results can be 
generalized to US older women, but may not be generalized to younger women or women 
residing in other countries in which do not provide full coverage of screening mammography.  
IV. Public Health Implications 
This study demonstrates no beneficial effect of metformin on breast cancer risk based on 
the study design that minimizes the potential for bias, supporting the notion that the anti-tumor 
ability of metformin observed in some of the previous studies is likely due to time-related biases 
[7]. Randomized clinical trials have been initiated to evaluate the effect of metformin on breast 
cancer incidence and outcomes, and will likely be in vain, given that the observational evidence 
leading to these trials likely suffered from avoidable biases. Thus, our findings may provide 
better allocation of medical resources in the future, and emphasize the importance of conducting 
observational studies with rigorous, state-of-the art design to avoid spurious effects with costly 
consequences.  
Our study is the first known study to explore the potential differential healthcare use in 
breast cancer screening examinations between metformin and sulfonylureas initiators. Detection 
bias is commonly of concern in observational studies of cancer [78, 79], including diabetes-
cancer studies [38, 80, 81], but has not been examined in metformin-breast cancer studies. Our 
findings indicate the existence of detection bias due to differential screening mammography 
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between metformin and sulfonylureas initiators. Researchers should be aware of the potential for 
more screening mammograms pre- and post-initiation when interpreting the findings of studies 
assessing the effects of metformin on breast cancer incidence. Additionally, our results also point 
to the potential inequality of healthcare use between metformin, the first-line treatment for type 2 
diabetes, and sulfonylureas, a therapeutic alternative. Although the causes are unknown, 
clinicians should advise and encourage diabetic patients to have cancer screening regularly.  
V. Future Research 
This study directs future research to several interesting topics to add to understanding of 
metformin’s anti-tumor ability and to address some limitations of our study. First, we observed a 
possible tendency towards a lower risk of breast cancer associated with metformin in African 
American women and speculate that metformin may have distinct effect for each subtype of 
breast cancer, given that incidences of subtype breast cancer vary by race. Thus, future research 
utilizing the large databases along with detailed information of breast cancer characteristics 
would be desire to examine the effect of metformin on the risks of breast cancer subtypes, in 
particular, focusing on African American.  
It is needed to identify patient and prescriber characteristics which predict prescribing 
metformin or sulfonylureas as initial treatment for type 2 diabetes. Recognition of these factors is 
informative to understand why metformin initiators were more frequently screened for breast 
cancer than sulfonylureas initiators, and will help clinicians and health policy makers to 
adequately promote screening examinations in these under-utilizing population, further 
improving disparity in healthcare use between metformin and sulfonylureas initiators. 
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Lastly, in addition to mammography, there are several common cancer screening 
examinations such as colonoscopy for colon cancer, prostate-specific antigen test for prostate 
cancer, and Pap smear for cervical cancer. And, potential anti-tumor ability of metformin has 
been also examined with these cancer sites. There is a need to explore potential differential use 
of these screening examinations between different anti-hyperglycemic drugs.  
VI. Conclusions 
This study provides no support for reduced risks of breast cancer after initiation of 
metformin compared with a clinical alternative, sulfonylureas, in older women. Our findings 
support the notion that reduced breast cancer risks in metformin users observed in previous 
studies is likely due to time-related biases, and emphasize the importance of conducting 
observational studies with rigorous, state-of-the art design to avoid observing spurious effects or 
missing real ones.  
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